Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Dec. 31, 2023 | Feb. 14, 2024 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001401395 | |
Entity Registrant Name | Neptune Wellness Solutions Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Dec. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-33526 | |
Entity Incorporation, State or Country Code | A8 | |
Entity Address, Address Line One | 545 Promenade du Centropolis, Suite 100 | |
Entity Address, City or Town | Laval | |
Entity Address, Country | CA | |
Entity Address, Postal Zip Code | H7T 0A3 | |
City Area Code | 450 | |
Local Phone Number | 687-2262 | |
Title of 12(b) Security | Common shares, no par value | |
Trading Symbol | NEPT | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 4,532,038 |
Condensed Consolidated Interim
Condensed Consolidated Interim Balance Sheets (Unaudited) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 1,232,905 | $ 1,993,257 |
Short-term investment | 17,642 | 17,540 |
Trade and other receivables | 3,893,358 | 7,507,333 |
Prepaid expenses | 1,839,657 | 1,025,969 |
Inventories | 9,616,172 | 13,006,074 |
Total current assets | 16,599,734 | 23,550,173 |
Property, plant and equipment | 1,035,423 | 1,403,264 |
Operating lease right-of-use assets | 1,599,231 | 1,941,347 |
Intangible assets | 1,308,849 | 1,607,089 |
Goodwill | 2,482,706 | 2,426,385 |
Total assets | 23,025,943 | 30,928,258 |
Current liabilities: | ||
Trade and other payables | 31,371,563 | 27,051,561 |
Current portion of operating lease liabilities | 339,620 | 339,620 |
Current portion of loans and borrowings | 25,984,400 | 7,538,369 |
Provisions | 14,809,758 | 2,948,340 |
Liability related to warrants | 911,790 | 3,156,254 |
Total current liabilities | 73,417,131 | 41,034,144 |
Operating lease liabilities | 1,816,377 | 2,017,888 |
Loans and borrowings, net of current portion | 0 | 15,412,895 |
Other liability | 14,000 | 24,000 |
Total liabilities | 75,247,508 | 58,488,927 |
Shareholders' Equity (Deficiency): | ||
Share capital - without par value (4,532,038 shares issued and outstanding as of December 31, 2023; 300,070 shares issued and outstanding as of March 31, 2023) | 327,944,215 | 321,946,102 |
Warrants issued, value | 6,648,437 | 6,155,323 |
Additional paid-in capital | 59,681,063 | 58,138,914 |
Accumulated other comprehensive loss | (14,925,620) | (14,538,830) |
Deficit | (410,595,259) | (383,641,363) |
Total deficiency attributable to equity holders of the Company | (31,247,164) | (11,939,854) |
Non-controlling interest | (20,974,401) | (15,620,815) |
Total shareholders' deficiency | (52,221,565) | (27,560,669) |
Commitments and contingencies | ||
Total liabilities and shareholders' deficiency | $ 23,025,943 | $ 30,928,258 |
Condensed Consolidated Interi_2
Condensed Consolidated Interim Balance Sheets (Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands | Dec. 31, 2023 | Mar. 31, 2023 |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, shares issued (in shares) | 4,532,038 | 300,070 |
Common stock, shares outstanding (in shares) | 4,532,038 | 300,070 |
Condensed Consolidated Interi_3
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue from sales, net of excise taxes of nil and nil (2022 - nil and $643,476 ) | $ 7,611,836 | $ 11,945,092 | $ 26,913,567 | $ 39,668,246 |
Royalty revenues | 23,963 | 263,816 | 70,961 | 766,736 |
Other revenues | (36,047) | 0 | (17,071) | 32,996 |
Total revenues | 7,599,752 | 12,208,908 | 26,967,457 | 40,467,978 |
Cost of sales other than impairment loss on inventories | (6,564,684) | (10,328,349) | (24,941,822) | (37,293,901) |
Impairment loss on inventories | 0 | 0 | (216,184) | (3,079,997) |
Total cost of sales | (6,564,684) | (10,328,349) | (25,158,006) | (40,373,898) |
Gross profit | 1,035,068 | 1,880,559 | 1,809,451 | 94,080 |
Research and development expenses | (727) | (28,836) | (47,266) | (451,121) |
Selling, general and administrative expenses | (18,732,654) | (8,727,323) | (34,541,474) | (35,188,695) |
Impairment loss related to intangible assets | 0 | 0 | 0 | (2,593,529) |
Impairment loss on assets held for sale | 0 | 0 | 0 | (15,346,119) |
Impairment loss on right of use assets | 0 | (271,057) | (75,409) | (271,057) |
Impairment loss related to goodwill | 0 | 0 | 0 | (7,570,471) |
Net gain on sale of property, plant and equipment | 0 | 84,998 | 0 | 170,000 |
Loss from operating activities | (17,698,313) | (7,061,659) | (32,854,698) | (61,156,912) |
Restructuring fees | (2,066,405) | 0 | (2,066,405) | 0 |
Finance income | 0 | 0 | 0 | 1,440 |
Finance costs | (1,602,981) | (1,362,776) | (6,570,787) | (2,658,305) |
Foreign exchange gain | 600,316 | 524,571 | 942,596 | 6,545,401 |
Loss on issuance of derivatives | 0 | (1,029,614) | (945,034) | (3,156,569) |
Gain on revaluation of derivatives | 1,596,901 | 8,367,871 | 7,186,846 | 16,083,681 |
Gain on settlement of liability | 0 | 66,169 | 0 | 66,169 |
Total other income (expense) | (1,472,169) | 6,566,221 | (1,452,784) | 16,881,817 |
Loss before income taxes | (19,170,482) | (495,438) | (34,307,482) | (44,275,095) |
Income tax expense | 0 | (2,013) | 0 | (14,543) |
Net loss | (19,170,482) | (497,451) | (34,307,482) | (44,289,638) |
Other comprehensive loss | ||||
Net change in unrealized foreign currency losses on translation of net investments in foreign operations (tax effect of nil for all periods) | (41,449) | (231,490) | (386,790) | (6,725,131) |
Total other comprehensive loss | (41,449) | (231,490) | (386,790) | (6,725,131) |
Total comprehensive loss | (19,211,931) | (728,941) | (34,694,272) | (51,014,769) |
Net income (loss) attributable to: | ||||
Equity holders of the Company | (17,749,338) | 1,288,110 | (26,953,896) | (33,893,698) |
Non-controlling interest | (1,421,144) | (1,785,561) | (7,353,586) | (10,395,940) |
Net loss | (19,170,482) | (497,451) | (34,307,482) | (44,289,638) |
Equity holders of the Company | (17,790,787) | 1,056,620 | (27,340,686) | (40,618,829) |
Non-controlling interest | (1,421,144) | (1,785,561) | (7,353,586) | (10,395,940) |
Total comprehensive loss | $ (19,211,931) | $ (728,941) | $ (34,694,272) | $ (51,014,769) |
Basic income (loss) per share attributable to: | ||||
Common Shareholders of the Company (in dollars per share) | $ (4.14) | $ 2.34 | $ (15.11) | $ (143) |
Diluted income (loss) per share attributable to: | ||||
Common Shareholders of the Company (in dollars per share) | $ (4.14) | $ 2.34 | $ (15.11) | $ (143) |
Basic weighted-average number of common shares outstanding (in shares) | 4,285,229 | 284,619 | 1,784,047 | 237,013 |
Dilutive weighted-average number of common shares outstanding (in shares) | 4,285,229 | 284,690 | 1,784,047 | 237,013 |
Condensed Consolidated Interi_4
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) (Parentheticals) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Excise taxes | $ 0 | $ 0 | $ 0 | $ 643,476 |
Net change in unrealized foreign currency losses on translation of net investments in foreign operations, tax effect | $ 0 | $ 0 | $ 0 | $ 0 |
Condensed Consolidated Interi_5
Condensed Consolidated Interim Statements of Changes in Equity (Deficiency) (Unaudited) - USD ($) | Total | Common Stock [Member] | Warrants [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Parent [Member] | Noncontrolling Interest [Member] |
Balance, shares (in shares) at Mar. 31, 2022 | 139,171 | |||||||
Balance, dollars at Mar. 31, 2022 | $ 60,837,599 | $ 317,051,125 | $ 6,079,890 | $ 55,980,367 | $ (7,814,163) | $ (323,181,697) | $ 48,115,522 | $ 12,722,077 |
Net loss for the period | (44,289,638) | 0 | 0 | 0 | 0 | (33,893,698) | (33,893,698) | (10,395,940) |
Other comprehensive loss for the period, dollars | (6,725,131) | 0 | 0 | 0 | (6,725,131) | 0 | (6,725,131) | 0 |
Total comprehensive loss | (51,014,769) | 0 | 0 | 0 | (6,725,131) | (33,893,698) | (40,618,829) | (10,395,940) |
Share-based payment, dollars | 2,832,438 | $ 0 | 0 | 2,832,438 | 0 | 0 | 2,832,438 | 0 |
Warrants exercised, shares (in shares) | 9,613 | |||||||
Warrants exercised, dollars | 1,769,000 | $ 1,769,000 | 0 | 0 | 0 | 0 | 1,769,000 | 0 |
Direct Offerings (including pre-funded warrants), net of issuance costs (in shares) | 128,854 | |||||||
Direct Offerings (including pre-funded warrants), net of issuance costs | 0 | $ 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total contributions by and distribution to equity holders, shares (in shares) | 155,448 | |||||||
Total contributions by and distribution to equity holders, dollars | 6,101,023 | $ 4,740,602 | 37,710 | 1,322,711 | 0 | 0 | 6,101,023 | 0 |
Common shares and warrants issued in connection with debt financing, shares (in shares) | 10,237 | |||||||
Common shares and warrants issued in connection with debt financing, dollars | 645,921 | $ 645,921 | 0 | 0 | 0 | 0 | 645,921 | 0 |
Warrants reclassified from liability | 37,710 | $ 0 | 37,710 | 0 | 0 | 0 | 37,710 | 0 |
RSUs released, net of withholding taxes, shares (in shares) | 6,744 | |||||||
RSUs released, net of withholding taxes, dollars | 815,954 | $ 2,325,681 | 0 | (1,509,727) | 0 | 0 | 815,954 | 0 |
Balance, shares (in shares) at Dec. 31, 2022 | 294,619 | |||||||
Balance, dollars at Dec. 31, 2022 | 15,923,853 | $ 321,791,727 | 6,117,600 | 57,303,078 | (14,539,294) | (357,075,395) | 13,597,716 | 2,326,137 |
Balance, shares (in shares) at Mar. 31, 2022 | 139,171 | |||||||
Balance, dollars at Mar. 31, 2022 | 60,837,599 | $ 317,051,125 | 6,079,890 | 55,980,367 | (7,814,163) | (323,181,697) | 48,115,522 | 12,722,077 |
Net loss for the period | (88,800,000) | |||||||
Balance, shares (in shares) at Mar. 31, 2023 | 300,070 | |||||||
Balance, dollars at Mar. 31, 2023 | (27,560,669) | $ 321,946,102 | 6,155,323 | 58,138,914 | (14,538,830) | (383,641,363) | (11,939,854) | (15,620,815) |
Balance, shares (in shares) at Sep. 30, 2022 | 213,081 | |||||||
Balance, dollars at Sep. 30, 2022 | 15,596,395 | $ 321,769,905 | 6,079,890 | 56,306,211 | (14,307,804) | (358,363,505) | 11,484,697 | 4,111,698 |
Net loss for the period | (497,451) | 0 | 0 | 0 | 0 | 1,288,110 | 1,288,110 | (1,785,561) |
Other comprehensive loss for the period, dollars | (231,490) | 0 | 0 | 0 | (231,490) | 0 | (231,490) | 0 |
Total comprehensive loss | (728,941) | 0 | 0 | 0 | (231,490) | 1,288,110 | 1,056,620 | (1,785,561) |
Share-based payment, dollars | 1,005,455 | $ 0 | 0 | 1,005,455 | 0 | 0 | 1,005,455 | 0 |
Total contributions by and distribution to equity holders, shares (in shares) | 81,538 | |||||||
Total contributions by and distribution to equity holders, dollars | 1,056,399 | $ 21,822 | 37,710 | 996,867 | 0 | 0 | 1,056,399 | 0 |
Warrants reclassified from liability | 37,710 | $ 0 | 37,710 | 0 | 0 | 0 | 37,710 | 0 |
RSUs released, net of withholding taxes, shares (in shares) | 1,324 | |||||||
RSUs released, net of withholding taxes, dollars | 13,234 | $ 21,822 | 0 | (8,588) | 0 | 0 | 13,234 | 0 |
Balance, shares (in shares) at Dec. 31, 2022 | 294,619 | |||||||
Balance, dollars at Dec. 31, 2022 | 15,923,853 | $ 321,791,727 | 6,117,600 | 57,303,078 | (14,539,294) | (357,075,395) | 13,597,716 | 2,326,137 |
Balance, shares (in shares) at Mar. 31, 2023 | 300,070 | |||||||
Balance, dollars at Mar. 31, 2023 | (27,560,669) | $ 321,946,102 | 6,155,323 | 58,138,914 | (14,538,830) | (383,641,363) | (11,939,854) | (15,620,815) |
Net loss for the period | (34,307,482) | 0 | 0 | 0 | 0 | (26,953,896) | (26,953,896) | (7,353,586) |
Other comprehensive loss for the period, dollars | (386,790) | 0 | 0 | 0 | (386,790) | 0 | (386,790) | 0 |
Total comprehensive loss | (34,694,272) | 0 | 0 | 0 | (386,790) | (26,953,896) | (27,340,686) | (7,353,586) |
Share-based payment, dollars | 1,516,920 | $ 0 | 0 | 1,516,920 | 0 | 0 | 1,516,920 | 0 |
Common shares issued in relation with the settlement of a litigation (in shares) | 2,522,936 | |||||||
Common shares issued in relation with the settlement of a litigation | 2,750,000 | $ 2,724,771 | 0 | 25,229 | 0 | 0 | 2,750,000 | 0 |
Warrants issued in connection with the Sprout Restructuring | 2,066,404 | $ 0 | 66,404 | 0 | 0 | 0 | 66,404 | 2,000,000 |
Warrants exercised, shares (in shares) | 1,348,652 | |||||||
Warrants exercised, dollars | 696 | $ 2,269,859 | (2,269,163) | 0 | 0 | 0 | 696 | 0 |
Direct Offerings (including pre-funded warrants), net of issuance costs (in shares) | 360,380 | |||||||
Direct Offerings (including pre-funded warrants), net of issuance costs | 3,699,356 | $ 1,003,483 | 2,695,873 | 0 | 0 | 0 | 3,699,356 | 0 |
Total contributions by and distribution to equity holders, shares (in shares) | 4,231,968 | |||||||
Total contributions by and distribution to equity holders, dollars | 10,033,376 | $ 5,998,113 | 493,114 | 1,542,149 | 0 | 0 | 8,033,376 | 2,000,000 |
Balance, shares (in shares) at Dec. 31, 2023 | 4,532,038 | |||||||
Balance, dollars at Dec. 31, 2023 | (52,221,565) | $ 327,944,215 | 6,648,437 | 59,681,063 | (14,925,620) | (410,595,259) | (31,247,164) | (20,974,401) |
Balance, shares (in shares) at Sep. 30, 2023 | 2,009,102 | |||||||
Balance, dollars at Sep. 30, 2023 | (38,259,532) | $ 325,219,444 | 6,582,033 | 59,222,340 | (14,884,171) | (392,845,921) | (16,706,275) | (21,553,257) |
Net loss for the period | (19,170,482) | 0 | 0 | 0 | 0 | (17,749,338) | (17,749,338) | (1,421,144) |
Other comprehensive loss for the period, dollars | (41,449) | 0 | 0 | 0 | (41,449) | 0 | (41,449) | 0 |
Total comprehensive loss | (19,211,931) | 0 | 0 | 0 | (41,449) | (17,749,338) | (17,790,787) | (1,421,144) |
Share-based payment, dollars | 433,494 | 0 | 0 | 433,494 | 0 | 0 | 433,494 | 0 |
Warrants issued in connection with the Sprout Restructuring | 2,066,404 | $ 0 | 66,404 | 0 | 0 | 0 | 66,404 | 2,000,000 |
Total contributions by and distribution to equity holders, shares (in shares) | 2,522,936 | |||||||
Total contributions by and distribution to equity holders, dollars | 5,249,898 | $ 2,724,771 | 66,404 | 458,723 | 0 | 0 | 3,249,898 | 2,000,000 |
Stock Issued During Period, Shares, Litigation Settlement (in shares) | 2,522,936 | |||||||
Stock Issued During Period, Value, Litigation Settlement | 2,750,000 | $ 2,724,771 | 0 | 25,229 | 0 | 0 | 2,750,000 | 0 |
Balance, shares (in shares) at Dec. 31, 2023 | 4,532,038 | |||||||
Balance, dollars at Dec. 31, 2023 | $ (52,221,565) | $ 327,944,215 | $ 6,648,437 | $ 59,681,063 | $ (14,925,620) | $ (410,595,259) | $ (31,247,164) | $ (20,974,401) |
Condensed Consolidated Interi_6
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||
Dec. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | |
Cash flows from operating activities: | |||||||
Net loss for the period | $ (19,170,482) | $ (497,451) | $ (34,307,482) | $ (44,289,638) | $ (88,800,000) | ||
Adjustments: | |||||||
Depreciation of property, plant and equipment | 449,166 | 652,196 | |||||
Non-cash lease expense | 255,270 | 385,800 | |||||
Amortization of intangible assets | 286,963 | 1,352,787 | |||||
Impairment loss on goodwill | 0 | 0 | 0 | 7,570,471 | |||
Share-based payment | 1,516,920 | 2,832,438 | |||||
Impairment loss on inventories | 0 | 0 | 216,184 | 3,079,997 | |||
Restructuring fees | 2,066,405 | 0 | 2,066,405 | 0 | |||
Expected credit losses | 145,551 | 496,846 | |||||
Loss on issuance of derivatives | 0 | 1,029,614 | 945,034 | 3,156,569 | |||
Net finance expense | 6,570,787 | 2,656,865 | |||||
Unrealized foreign exchange (gain) loss | (180,978) | (6,545,401) | |||||
Interest received | 0 | 1,440 | |||||
Interest paid | (2,027,322) | (215,019) | |||||
Gain on settlement of liability | 0 | (66,169) | 0 | (66,169) | |||
Revaluation of derivatives | (1,596,901) | (8,367,871) | (7,186,846) | (16,083,681) | |||
Impairment loss on assets held for sale | 0 | 0 | $ 0 | 0 | 15,346,119 | ||
Impairment loss on right-of-use assets | 0 | 271,057 | 75,409 | 271,057 | |||
Impairment loss on intangibles | 0 | 0 | 0 | 2,593,529 | |||
Payment of lease liabilities | (209,194) | (253,795) | |||||
Income tax expense | 0 | 2,013 | 0 | 14,543 | |||
Net gain on sale of property, plant and equipment | 0 | (84,998) | 0 | (170,000) | |||
Changes in operating assets and liabilities | 23,819,010 | 6,543,514 | |||||
Income taxes paid | 0 | (360) | |||||
Net cash used in operating activities | (7,565,123) | (20,669,892) | (28,600,000) | ||||
Cash flows from investing activities: | |||||||
Proceeds on sale of assets | 0 | 170,000 | |||||
Net proceeds from the sale of Cannabis assets | 0 | 3,121,778 | |||||
Acquisition of property, plant and equipment | (79,208) | (601,743) | |||||
Net cash provided by investing activities | (79,208) | 2,690,035 | |||||
Cash flows from financing activities: | |||||||
Repayment of loans and borrowings | (30,921,043) | 0 | |||||
Net increase in loans and borrowings, net of financing fees | 30,917,703 | 3,800,000 | |||||
Withholding taxes paid pursuant to the settlement of non-treasury RSUs | 0 | (574,153) | |||||
Gross proceeds from the issuance of shares and warrants through a Direct Offering | 8,499,845 | 5,000,002 | |||||
Proceeds from the issuance of shares and warrants through a Registered Direct Offering Priced At-The-Market and Concurrent Private Placement | 0 | 6,000,002 | |||||
Shares and warrants issuance costs | (1,521,640) | (1,330,211) | |||||
Proceeds from exercise of options and pre-funded warrants | 696 | 65 | |||||
Net cash provided by (used in) financing activities | 6,975,561 | 12,895,705 | |||||
Foreign exchange loss on cash and cash equivalents | (91,582) | (238,166) | |||||
Net increase (decrease) in cash and cash equivalents | (760,352) | (5,322,318) | |||||
Cash and cash equivalents, beginning of period | $ 3,404,023 | 1,993,257 | 8,726,341 | 8,726,341 | |||
Cash and cash equivalents as at December 31, 2023 and 2022 | 1,232,905 | $ 1,993,257 | 3,404,023 | 3,404,023 | 1,232,905 | 3,404,023 | $ 1,993,257 |
Cash and cash equivalents is comprised of: | |||||||
Cash | $ 1,232,905 | $ 3,404,023 | $ 3,404,023 | 1,232,905 | 3,404,023 | ||
Changes in operating assets and liabilities | |||||||
Trade and other receivables | 3,954,320 | 2,489,793 | |||||
Prepaid expenses | (1,746,741) | 798,493 | |||||
Inventories | 3,032,798 | (2,544,635) | |||||
Trade and other payables | 6,727,215 | 1,599,623 | |||||
Deferred revenues | 0 | (285,006) | |||||
Provisions | 11,861,418 | 4,550,934 | |||||
Other liabilities | (10,000) | (65,688) | |||||
Changes in operating assets and liabilities | $ 23,819,010 | $ 6,543,514 |
Note 1 - Reporting Entity
Note 1 - Reporting Entity | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Reporting entity: Neptune Wellness Solutions Inc. (the "Company" or "Neptune") is incorporated under the Business Corporations Act (Québec) (formerly Part 1A 100 545 9354 7537 9418 1252 Neptune is a diversified and fully integrated health and wellness company. Through its flagship consumer-facing brands, Neptune Wellness, Forest Remedies™, Biodroga, MaxSimil®, Sprout®, Nosh® and NurturMe®, Neptune is redefining health and wellness by building a broad portfolio of natural, plant-based, sustainable and purpose-driven lifestyle brands and consumer packaged goods products in key health and wellness markets, including nutraceuticals and organic baby food. On June 8, 2022, 2021 two 1 2 On November 20, 2023, three 10 30 22 2024 may not no For various reasons uncovered during the diligence process, the Company has concluded that it is no no Sale of Cannabis Assets On October 17, 2022, not September 30, 2022. November 9, 2022, Share consolidations and delisting from TSX On June 9, 2022, first one 1 thirty-five June 13, 2022. June 13, 2022. September 7, 2023, second one 1 forty September 8, 2023. September 8, 2023. On July 29, 2022, not August 15, 2022. Going concern These condensed consolidated interim financial statements have been prepared on a going concern basis, which presumes that the Company will continue realizing its assets and discharging its liabilities in the normal course of business for the foreseeable future. The Company has incurred significant operating losses and negative cash flows from operations since inception. To date, the Company has financed its operations primarily through the public offering and private placement of Common Share units, consisting of Common Shares and warrants, convertible debt, the proceeds from research grants and research tax credits, and the exercises of warrants, rights and options. For the nine December 31, 2023 $ , $ December 31, 2023 March 31, 2023 $ December 31, 2023 not 8 no 2024. As of the date these financial statements are authorized for issuance, there is minimal cash balance. The Company requires funding in the very near term in order to continue its operations. The Company’s lack of cash resources and current share price may may These conditions cast substantial doubt about the Company's ability to continue as a going concern. Going forward, the Company will seek additional financing in various forms. To achieve the objectives of its business plan, Neptune plans to raise the necessary funds through additional securities offerings and the establishment of strategic alliances. The ability of the Company to complete the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside of the Company’s control and subject to market conditions. The Company’s business plan is dependent upon, among other things, its ability to achieve profitability, continue to obtain adequate ongoing debt and/or equity financing to finance operations within and beyond the next twelve These consolidated financial statements do not not |
Note 2 - Basis of Preparation
Note 2 - Basis of Preparation | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | 2. Basis of preparation: (a) Accounting framework: These condensed consolidated interim financial statements have been prepared in accordance with United States generally accepted accounting principles (U. S. GAAP) as codified in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC). (b) Functional and reporting currency: Effective March 31, 2022, The assets and liabilities of foreign operations with a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate in effect at the balance sheet date. Revenue and expenses are translated at the monthly average exchange rates for the period. Differences arising from the exchange rate changes are recorded within foreign currency translation adjustments, a component of other comprehensive income (loss). Transactions in foreign currencies are translated to the respective functional currencies of the Company’s subsidiaries at the average exchange rates for the period. The monetary items denominated in currencies other than the functional currency of a subsidiary are translated at the exchange rates prevailing at the balance sheet date. Non-monetary items denominated in currencies other than the functional currency are translated at historical rates. Gains and losses resulting from re-measurement are recorded in the Company’s condensed consolidated interim statement of loss and comprehensive loss as foreign exchange gain (loss). As a result of the divestiture of its Canadian cannabis business, a significant portion of its remaining revenues, expenses, assets and liabilities are denominated in US dollars. In addition, and as a result of the increasing operations in the U.S., Neptune changed its functional currency from Canadian dollars (“CAD”) to U.S. dollars (“USD”), effective October 1, 2022. All assets and liabilities were reported using the same USD values as previously reported under the USD reporting currency described above. The cumulative translation account in Neptune was effectively frozen and the accumulated balance as at September 30, 2022 October 1, 2022 not October 1, 2022, 2020 2021 no 11 13 (c) Use of estimates: The preparation of the condensed consolidated interim financial statements in accordance with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities at the date of the condensed consolidated interim financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Estimates are based on management’s best knowledge of current events and actions that the Company may Estimates include the following: ● Estimating the write down of inventory. ● Estimating expected credit losses for receivables. ● Estimating the recoverable amount of non-financial assets, to determine and measure impairment losses on goodwill, intangibles, and property, plant and equipment. ● Estimating the lease term of contracts with extension options and termination options. ● Estimating the lease liabilities and related right-of-use assets. ● Estimating the revenue from contracts with customers subject to variable consideration. ● Estimating the fair value of bonus, options and warrants that are based on market and non-market conditions (note 13 ● Estimating the fair value of the identifiable assets acquired, liabilities assumed, and consideration transferred of the acquired business, including the related contingent consideration and call option. ● Estimating the litigation provision as it depends upon the outcome of proceedings (note 9 |
Note 3 - Significant Accounting
Note 3 - Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Significant accounting policies: These unaudited Condensed Consolidated Interim Financial Statements have been prepared in accordance U.S. GAAP and on a basis consistent with those accounting principles followed by the Company and disclosed in note 2 March 31, 2023, (a) Basis of consolidation: These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated from the Company’s condensed consolidated interim financial statements. On February 10, 2021, November 3, 2023, 4 (b) New standards and interpretations: New standards In October 2021, 2021 08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers 805, 2021 08 1 2 2021 08 December 15, 2022. 2021 08 April 1, 2023, In June 2016, 2016 13, 326 2016 13” 2016 13 December 15, 2019, first 2019. November 2019, No. 2019 10, 326 815 842 2019 10” two 2016 13. December 15, 2019, 2016 13, December 15, 2022. 2016 13 April 1, 2023, Accounting pronouncements not adopted No 2023 |
Note 4 - Business Combination a
Note 4 - Business Combination and Disposal | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Mergers, Acquisitions and Dispositions Disclosures [Text Block] | 4. Business combination and disposal: (a) Divesture of the Cannabis assets: On June 8, 2022, one September 30, 2022, third October 16, 2022 March 31, 2023 November 9, 2022. (b) Acquisition of a controlling interest in Sprout Foods and subsequent planned Spinout: On February 10, 2021, January 1, 2023 December 31, 2023. January 1, 2023. 2.3x 12.0x 3.0x 15.0x March 31, 2022, $nil, December 31, 2023 $nil. On September 18, 2023, August 17, 2023 ( 8 no may not not On November 3, 2023, NGV three nine December 31, 2023 |
Note 5 - Inventories
Note 5 - Inventories | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 5. Inventories: December 31, 2023 March 31, 2023 Raw materials $ 5,126,337 $ 5,314,450 Work in progress 98,727 — Finished goods 4,186,124 7,360,850 Supplies and spare parts 204,984 330,774 $ 9,616,172 $ 13,006,074 During the three nine December 31, 2023 nil 2022 nil three nine December 31, 2022 not |
Note 6 - Property, Plant and Eq
Note 6 - Property, Plant and Equipment | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 6. Property, plant and equipment: As at September 30, 2022, nil three nine December 31, 2022. |
Note 7 - Goodwill and Intangibl
Note 7 - Goodwill and Intangible Assets | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 7. Goodwill and intangible assets: The Company assesses at each reporting date whether there is an indication that an asset group or a reporting unit may During the fourth March 31, 2023, fourth March 31, 2023, fourth March 31, 2023, During the third March 31, 2023, third During the second March 31, 2023, second 2022 September 30, 2022. September 30, 2022. no may As part of the impairment testing process, during the above periods in fiscal 2023, not Cash flows were projected based on past experience, actual operating results and the three 3 not There was no change to the fair value of the Biodroga goodwill, aside from currency translation induced changes. The aggregate amount of goodwill is allocated to each reporting unit as follows: December 31, 2023 March 31, 2023 Biodroga $ 2,482,706 $ 2,426,385 $ 2,482,706 $ 2,426,385 |
Note 8 - Loans and Borrowings
Note 8 - Loans and Borrowings | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 8. Loans and borrowings: December 31, 2023 March 31, 2023 Loans and borrowings: Promissory note originally of $ 10,000,000 13,000,000 10.0 1.00 3,000,000 9,317 570,185 15.0 10.0 5.0 7.5 $ 18,092,845 $ 15,622,508 Promissory note of $ 250,000 10.0 1.00 920 75,736 291,057 218,517 Promissory notes totaling $ 550,000 10.0 1.00 3,659 96,578 624,638 496,061 Senior secured notes (the "Notes") issued by the Company on January 12, 2023 for gross proceeds of $ 4,000,000 12 16.5 6 200,000 100,000 100,000 24 713,320 850,000 338,320 — 3,607,116 Accounts receivable factoring facility contracted by Sprout on January 25, 2023, to which an inventory financing through an Invoice Purchase and Security Agreement partnership with Alterna Capital Solutions LLC, was added effective April 21, 2023. The maximum available has been amended to $ 7.5 5.0 1 8 5,258,548 2,762,110 Promissory note of $ 300,000 10.0 1.00 111,111 0.54 37,723 323,892 244,952 Accounts receivable factoring facility contracted by Biodroga on November 8, 2023 through an Invoice Purchase and Security Agreement ("PSA") partnership with Alterna Capital Solutions LLC (the "Lender"), which includes an inventory financing rider (the "Rider"). The maximum amount potentially available to be deployed by the Lender at any given time pursuant to the PSA and Rider is $ 3 1 8 1 9.5 1,393,420 — Loans and borrowings 25,984,400 22,951,264 Less current portion of loans and borrowings 25,984,400 7,538,369 Loans and borrowings, net of current portion $ — $ 15,412,895 On November 17, 2023, November 8, 2023, November 8, 2023, may not may twelve On November 6, 2023, June 30, 2025 fifteen June 30, 2024, July 1, 2024 seven one and seven one five 360 On October 13, 2023, On August 17, 2023, November 13, 2023 ( June 30, 2025 4 no November 3, 2023. On May 22, 2023, January 12, 2023. May 15, 2023, July 31, 2023, thirty 1 July 31, 2023. March 31, 2023, twenty four August 22, 2023. On May 10, 2023, April 21, 2023. January 25, 2023, On April 27, 2023, February 1, 2024 December 31, 2024, December 31, 2023, January 1, 2024. The Company did not February 1, 2024 may During the three nine December 31, 2023 2022 nil three nine December 31, 2023 2022 |
Note 9 - Provisions
Note 9 - Provisions | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Legal Matters and Contingencies [Text Block] | 9. Provisions (a) During the year ended March 31, 2019, February 23, 2001 February 2021. not December 31, 2023 March 31, 2023 three nine December 31, 2023 three nine December 31, 2022 no September 20, 2022, not (b) In September 2020, May 9, 2019, April 2022 August 1 August 5, 2022. June 15, 2022, one April 2021 ( June 2021). July 7, 2022, April 13, 2023, August 23, 2023, eight September 29, 2023, not December 31, 2023 March 31, 2023 (c) A supplier of cannabis initiated a lawsuit against the Company's subsidiary, 9354 7537 "9354" 9354 9354 November 2021, March 23, 2022, 9354 9354 June 30, 2022, July 13, 2022. June 30, 2022, three June 30, 2022. March 31, 2023, October 12, 2022. December 31, 2023 nil. (d) On March 16, 2021, 10 20 1934, October 21, 2022, March 16, 2023 first March 22, 2023. April 21, 2023, May 4, 2023 October 10, 2023. December 31, 2023 nil. (e) Neptune Health and Wellness Innovation, Inc. ("Innovation") entered into a warehousing agreement with Carolina Rework Solutions on August 10, 2020, not April 2024. December 31, 2023 March 31, 2023 (f) Baxters Food Group Limited, the parent company of two December 11, 2023. December 31, 2023 March 31, 2023 nil (g) As at December 31, 2023 March 31, 2023 |
Note 10 - Liability Related to
Note 10 - Liability Related to Warrants | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Liability Related to Warrants [Text Block] | 10. Liability related to warrants: The Company has issued common shares, pre-funded warrants and warrants as part of its financing arrangements which are exercisable for a variable number of shares. Common shares and pre-funded warrants are classified as equity. Warrants are classified as liabilities rather than equity. As of October 1, 2022, 2020 2021 no note11 On September 21, 2023, "September 2023 five September 26, 2023. "September 2023 December 31, 2023 September 2023 Proceeds of the $4,500,000 September 2023 first September 2023 1. nine December 31, 2023 In connection with the offering closed on September 26, 2023, October 2020, February 2021, March 2022, June 2022, October 2022 May 2023, October 22, 2025 June 23, 2029, five June 23, 2029. On May 11, 2023, "May 2023 five May 15, 2023. "May 2023 September 26, 2023, September 26, 2028. December 31, 2023 May 2023 Proceeds of the $4,000,000 May 2023 first May 2023 1. nine December 31, 2023 In connection with the offering closed on May 15, 2023, March 2022, June 2022, October 2022, September 14, 2023 June 23, 2029, five June 23, 2029 first 2024. On January 12, 2023, "January 2023 5 On October 11, 2022, "October 2022 five May 15, 2023, September 26, 2023, September 26, 2028. As of October 1, 2022, 2020 2021 no not On June 23, 2022, "June 2022 "June 2022 June 2022 June 2022 October 6, 2022, two May 15, 2023, September 26, 2023, September 26, 2028, June 23, 2029, October 6, 2022. Proceeds of the June 2022 first no June 24, 2022, March 31, 2023 During the month of August 2022, The fair value of the Series C Warrants and Series D Warrants liability was determined using the Binomial model. Warrants are revalued each period-end at fair value and accounted for in the Company's condensed consolidated interim statement of loss and comprehensive loss under “gain on revaluation of derivatives”. Changes in the value of the liability related to the warrants for the nine December 31, 2023 2022 Warrants Amount Outstanding as at March 31, 2022 48,151 $ 5,570,530 Warrants issued during the period 257,709 14,156,571 Warrants exercised during the period (29,351 ) (1,769,000 ) Warrants reclassified to equity during the period (12,435 ) (37,710 ) Net revaluation gain (16,083,681 ) Movements in exchange rates (392,652 ) Outstanding as at December 31, 2022 264,074 $ 1,444,058 Outstanding as at March 31, 2023 285,325 $ 3,156,254 Warrants issued during the period 2,103,034 3,997,348 Net revaluation gain (6,241,812 ) Outstanding as at December 31, 2023 2,388,359 $ 911,790 The following table provides the relevant information on the outstanding warrants as at December 31, 2023 Reference Date of issuance Number of warrants outstanding Number of warrants exercisable Exercise price Expiry date Series A Warrants March 14, 2022 17,858 17,858 $ 2.50 September 26, 2028 Series B Warrants March 14, 2022 17,858 17,858 $ 2.50 September 26, 2028 Series C Warrants June 23, 2022 19,289 19,289 $ 2.50 September 26, 2028 Series C Warrants June 23, 2022 24,320 24,320 $ 2.50 June 23, 2029 Series D Warrants June 23, 2022 24,320 24,320 $ 2.50 September 26, 2028 Series E Warrants October 11, 2022 53,477 53,477 $ 64.80 October 11, 2027 Series E Warrants October 11, 2022 106,952 106,952 $ 2.50 September 26, 2028 January 2023 Warrants January 12, 2023 21,251 21,251 $ 21.20 January 12, 2028 May 2023 Warrants May 15, 2023 30,382 30,382 $ 13.20 May 15, 2028 May 2023 Warrants May 15, 2023 272,652 272,652 $ 2.50 September 26, 2028 September 2023 Warrants September 26, 2023 1,800,000 1,800,000 $ 2.50 September 26, 2028 2,388,359 2,388,359 $ 4.20 The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value for the nine December 31, 2023 2022 2020 Warrants 2021 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ — $ 309,769 $ — $ 306,704 Warrants reclassified to equity during the period — (19,058 ) — (18,652 ) Change in fair value to date of transfer to equity — (279,056 ) — (276,527 ) Translation effect — (11,655 ) — (11,525 ) Balance - end of period $ — $ — $ — $ — Series A Warrants Series B Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 106,207 $ 3,270,816 $ 3,641 $ 1,683,241 Change in fair value (99,242 ) (3,099,783 ) 3,324 (1,622,926 ) Translation effect — (136,418 ) — (59,975 ) Balance - end of period $ 6,965 $ 34,615 $ 6,965 $ 340 Series C Warrants Series D Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 494,289 $ — $ 153,598 $ — Warrants issued during the period — 4,046,836 — 3,080,121 Warrants exercised during the period — (365,224 ) — (1,403,776 ) Change in fair value (477,092 ) (3,339,370 ) (144,113 ) (1,337,675 ) Translation effect — (121,760 ) — (51,319 ) Balance - end of period $ 17,197 $ 220,482 $ 9,485 $ 287,351 Series E Warrants January 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 2,046,082 $ — $ 352,437 $ — Warrants issued during the period — 7,029,614 — — Change in fair value (1,996,435 ) (6,128,344 ) (347,443 ) — Balance - end of period $ 49,647 $ 901,270 $ 4,994 $ — May 2023 Warrants September 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ — $ — $ — $ — Warrants issued during the period 2,025,247 — 1,972,101 — Change in fair value (1,910,710 ) — (1,270,101 ) — Balance - end of period $ 114,537 $ — $ 702,000 $ — The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions: Series A Warrants Series B Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Share price $ 0.53 $ 12.80 $ 0.53 $ 12.80 Exercise price $ 2.50 $ 448.00 $ 2.50 $ 448.00 Dividend yield — — — — Risk-free interest 3.86 % 4.02 % 3.86 % 4.75 % Remaining contractual life (years) 4.75 4.71 4.75 0.71 Expected volatility 133.8 % 94.2 % 133.8 % 135.7 % Series C Warrants Series D Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Share price $ 0.53 $ 12.80 $ 0.53 $ 12.80 Exercise price $ 2.50 $ 92.80 $ 2.50 $ 92.80 Dividend yield — — — — Weighted average risk-free interest 3.86 % 4.05 % 3.86 % 4.58 % Weighted average remaining contractual life (years) 5.16 4.48 4.75 1.48 Weighted average expected volatility 129.8 % 94.1 % 133.8 % 112.4 % Series E Warrants January 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 January 12, 2023 (Grant date) Share price $ 0.53 $ 12.80 $ 0.53 $ 21.20 Weighted average exercise price $ 2.50 $ 64.80 $ 2.50 $ 21.20 Dividend yield — — — — Weighted average risk-free interest 3.89 % 4.02 % 3.99 % 3.53 % Weighted average remaining contractual life (years) 4.18 4.78 4.04 5.00 Weighted average expected volatility 137.1 % 93.6 % 141.6 % 98.2 % May 2023 Warrants September 2023 Warrants December 31, 2023 May 15, 2023 (Grant date) December 31, 2023 September 26, 2023 (Grant date) Share price $ 0.53 $ 8.80 $ 0.53 $ 1.35 Exercise price $ 2.50 $ 13.20 $ 2.50 $ 2.50 Dividend yield — — — — Risk-free interest 3.87 % 3.46 % 3.86 % 4.62 % Remaining contractual life (years) 4.71 5.00 4.50 5.00 Expected volatility 134.1 % 110.9 % 133.8 % 126.8 % The Company measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level 3 |
Note 11 - Capital and Other Com
Note 11 - Capital and Other Components of Equity | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | 11. Capital and other components of equity: (a) Share capital: Authorized capital stock: Unlimited number of shares without par value: ● Common shares Preferred shares, issuable in series, rights, privileges and restrictions determined at time of issuance: ● Series A preferred shares, non-voting, non-participating, fixed, preferential, and non-cumulative dividend of 5% of paid-up capital, exchangeable at the holder’s option under certain conditions into common shares (none issued and outstanding). All issued shares are fully paid. (b) Share options exercised: During the three nine December 31, 2023 2022 (c) DSUs released: During the three nine December 31, 2023 2022 (d) RSUs released: During the three nine December 31, 2023 During the nine December 31, 2022, (e) Restricted shares: During the three nine December 31, 2023 2022 (f) Warrants: On November 3, 2023, 4 April 7, 2028 three nine December 31, 2023 On September 26, 2023, September 2023 10, “September 2023 September 2023 September 2023 December 31, 2023 September 2023 On May 15, 2023, May 2023 10, “May 2023 May 2023 December 31, 2023 May 2023 On March 10, 2023, "March 2023 March 2023 As of October 1, 2022, 2020 2021 no not September 26, 2023, five On June 23, 2022, June 2022 10, “June 2022 June 2022 June 2022 June 2022 June 2022 June 24, 2022, Changes in the value of equity related to the warrants were as follows: December 31, 2023 December 31, 2022 Weighted Weighted average Number of average Number of exercise price warrants exercise price warrants Warrants outstanding at April 1, 2023 and 2022 $ 4,924.69 19,625 $ 13,013.78 4,412 Issued 0.0010 1,835,147 0.0040 16,139 Reclassification from liability related to warrants — — 3,150.0000 12,435 Exercised 0.0007 (1,348,652 ) 0.0040 (16,139 ) Warrants outstanding at December 31, 2023 and December 31, 2022 $ 190.96 506,120 $ 5,733.19 16,847 Warrants exercisable at December 31, 2023 and December 31, 2022 $ 190.96 506,120 $ 5,733.19 16,847 Warrants of the Company classified as equity are composed of the following as at December 31, 2023 March 31, 2023 December 31, 2023 March 31, 2023 Number Number Number Number outstanding exercisable Amount outstanding exercisable Amount Warrants IFF (i) 1,429 1,429 $ 1,630,210 1,429 1,429 $ 1,630,210 Warrants AMI (ii) 2,983 2,983 4,449,680 2,983 2,983 4,449,680 2020 Warrants (iii) 7,524 7,524 19,058 7,524 7,524 19,058 2021 Warrants (iv) 4,911 4,911 18,652 4,911 4,911 18,652 March 2023 Warrants 2,778 2,778 37,723 2,778 2,778 37,723 September 2023 Pre-Funded Warrants 394,000 394,000 426,710 — — — MSEC Warrants 92,495 92,495 66,404 — — — 506,120 506,120 $ 6,648,437 19,625 19,625 $ 6,155,323 (i) During the year ended March 31, 2020, November 7, 2024. March 31, 2022 (ii) During the year ended March 31, 2020, October 3, 2024 February 5, 2025. March 31, 2021 (iii) During the year ended March 31, 2021, “2020 October 22, 2025. October 20, 2020, April 22, 2021 October 22, 2025. 2020 October 1, 2022 September 26, 2023, 2020 September 26, 2028 (iv) On February 19, 2021, “2021 August 19, 2026. February 17, 2021, August 19, 2021 August 19, 2026. 2021 October 1, 2022 September 26, 2023, 2021 September 26, 2028 (g) Common shares issued in connection with debt financing: On February 15, 2023, November 8, 2022, On September 9, 2022, On July 13, 2022, (h) Direct Offerings: On September 26, 2023, “September 2023 "September 2023 September 2023 September 2023 September 2023 10 September 2023 September 2023 September 2023 September 2023 September 2023 September 2023 September 2023 first September 2023 September 2023 September 2023 1. September 2023 three nine December 31, 2023 On May 15, 2023, “May 2023 "May 2023 May 2023 May 2023 May 2023 10 May 2023 May 2023 May 2023 May 2023 May 2023 May 2023 May 2023 first May 2023 1. May 2023 three nine December 31, 2023 On June 23, 2022, "June 2022 "June 2022 June 2022 June 2022 October 6, 2022, two June 2022 first no 1. June 24, 2022, August 2022, September 26, 2023, September 26, 2028. (g) Common shares issued in relation with the settlement of a litigation: On October 10, 2023, March 16, 2021 ( 9 |
Note 12 - Non-controlling Inter
Note 12 - Non-controlling Interest | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | 12. Non-controlling interest: Following the Sprout Restructuring Agreement (see Note 4 November 3, 2023. Name Country of incorporation December 31, 2023 March 31, 2023 Sprout United States of America 10.5 % 49.9 % As for the weighted average proportion of equity interest held by non-controlling interests for the three nine December 31, 2023 December 31, 2022 Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Sprout 23.8% 49.9% 41.2% 49.9% The summarized financial information of Sprout is provided below. This information is based on amounts before inter-company eliminations and include the effects of the Company’s purchase price adjustments. Summarized statement of loss and comprehensive loss: Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Revenue from contracts with customers $ 4,868,817 $ 8,380,966 $ 18,928,571 $ 24,903,038 Cost of sales (4,347,787 ) (7,825,211 ) (18,896,730 ) (23,748,469 ) Selling, general and administrative expenses (8,327,436 ) (3,184,805 ) (16,476,345 ) (9,412,606 ) Impairment loss on goodwill and intangible assets — — — (10,164,000 ) Finance costs (1,454,080 ) (934,685 ) (4,704,644 ) (2,396,967 ) Loss before tax (9,260,486 ) (3,563,735 ) (21,149,148 ) (20,819,004 ) Income tax expense — (14,543 ) — (14,543 ) Net loss (9,260,486 ) (3,578,278 ) (21,149,148 ) (20,833,547 ) Total comprehensive loss (9,260,486 ) (3,578,278 ) (21,149,148 ) (20,833,547 ) Loss attributable to the subsidiary's non-controlling interest (1,421,144 ) (1,803,089 ) (7,353,586 ) (2,220,145 ) Comprehensive loss attributable to the subsidiary's non-controlling interest $ (1,421,144 ) $ (1,775,189 ) $ (7,353,586 ) $ (2,220,145 ) Summarized statement of balance sheets: December 31, 2023 March 31, 2023 Current assets $ 7,712,019 12,382,450 Non-current assets 5,403 9,788 Current liabilities 43,561,652 12,938,219 Non-current liabilities 3,659,307 35,789,746 Total equity (deficiency) (39,503,537 ) (36,335,727 ) Attributable to: Equity holders of the Company (46,872,028 ) (20,714,912 ) Non-controlling interest $ 7,368,491 $ (15,620,815 ) Summarized statement of cash flow: Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Cash flow provided by (used in) operating activities $ 85,994 $ (1,873,210 ) $ (2,491,563 ) $ (5,798,310 ) Cash flow provided by investing activities — — — — Cash flow provided by (used in) financing activities (409,260 ) 1,999,408 2,496,437 5,249,408 Net increase (decrease) in cash and cash equivalents $ (323,266 ) $ 126,198 $ 4,874 $ (548,902 ) ( 1 |
Note 13 - Share-based Payment
Note 13 - Share-based Payment | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 13. Share-based payment: Under the Company’s share-based payment arrangements, stock-based compensation expenses of and respectively were recognized on equity share based awards for the three nine December 31, 2023 and expenses of $ nil and $nil three nine December 31, 2023 ( 2022 - respectively and for equity-based awards and $110,859 and $3,263,437 for liability-based awards). As at December 31, 2023 (a) Company stock option plan: (i) Stock option plan: The Company has established a stock option plan for directors, officers, employees and consultants. The exercise price of the stock options granted under the plan is not ten no not The number and weighted average exercise prices of stock options are as follows: 2023 2022 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1st, 2023 and 2022 $ 729.32 10,443 $ 1,496.49 7,385 Granted — — 64.14 5,744 Forfeited/Cancelled 100.03 (2,978 ) 640.00 (1,650 ) Expired — — 2,028.40 (956 ) Options outstanding at December 31, 2023 and 2022 $ 975.98 7,465 $ 742.00 10,523 Options exercisable at December 31, 2023 and 2022 $ 995.86 6,971 $ 1,570.00 3,258 December 31, 2023 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $62.00 - $64.00 3.63 36 12 $ 62.00 $64.01 - $242.80 3.74 2,850 2,850 65.60 $242.81 - $896.00 3.11 465 167 470.30 $896.01 - $1,129.20 2.62 2,143 2,143 1,022.00 $1,129.21 - $6,437.13 5.32 1,971 1,799 2,493.45 3.79 7,465 6,971 $ 995.86 The weighted average fair value of the options granted to employees during the three nine December 31, 2023 nil 2022 nine December 31, 2023 2022 three nine December 31, 2023 2022 December 31, 2023 2022 (ii) Non-market performance options: On July 8, 2019, July 8, 2029. ten December 31, 2023 not December 31, 2023 2022 three nine December 31, 2023 2022 (iii) Market performance options: On July 8, 2019, July 8, 2029. ten The number and weighted average exercise prices of market performance options are as follows: 2023 2022 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1, 2023 and 2022 $ 6,202.00 3,929 $ 6,202.00 3,929 Options outstanding at December 31, 2023 and 2022 $ 6,202.00 3,929 $ 6,202.00 3,929 Options exercisable at December 31, 2023 and 2022 $ 6,202.00 536 $ 6,202.00 536 Stock-based compensation recognized under this plan amounted to $382,053 and $1,297,555 respectively for the three nine December 31, 2023 2022 December 31, 2023 2022 (b) Deferred Share Units and Restricted Share Units: The Company has established an equity incentive plan for employees, directors and consultants of the Company. The plan provides for the issuance of restricted share units, performance share units, restricted shares, deferred share units and other share-based awards, subject to restricted conditions as may may (i) Deferred Share Units ("DSUs") The number and weighted average share prices of DSUs are as follows: 2023 2022 Weighted Weighted average average share Number of share Number of Notes price DSUs price DSUs DSUs outstanding at April 1, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 DSUs outstanding at December 31, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 DSUs exercisable at December 31, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 Of the 110 DSUs outstanding as at December 31, 2023 2022 nine December 31, 2023 twelve 2022 nil Stock-based compensation recognized under this plan amounted to $ nil nil three nine December 31, 2023 2022 $nil December 31, 2023 nil December 31, 2022 (ii) Restricted Share Units (‘’RSUs’’) During the year ended March 31, 2020, three March 31, 2021, nine December 31, 2023 $nil 2022 2023 2022 Weighted Weighted average average share Number of share Number of Notes price RSUs price RSUs RSUs outstanding at April 1st, 2023 and 2022 $ 2,401.60 71 $ 2,389.92 626 Granted — — 132.40 10,917 Forfeited — — 770.00 (391 ) Released through the issuance of common shares 11(d) — — 224.00 (6,743 ) Withheld as payment of withholding taxes 11(d) — — 224.00 (4,338 ) RSUs outstanding at December 31, 2023 and 2022 $ 2,401.60 71 $ 2,401.60 71 RSUs exercisable at December 31, 2023 and 2022 $ 2,401.60 71 $ 2,401.60 71 Stock-based compensation recognized under this plan amounted to $nil nil respectively for the three nine December 31, 2023 ( 2022 - $ and $ ). Unrecognized compensation cost at December 31, 2023 is $ nil ( 2022 - $ nil unrecognized compensation cost with a weighted average remaining life of years). On November 14, 2021, July 1, 2021 July 31, 2022. December 31, 2021, not December 31, 2021, The balance of the liability accrual to the CEO is $8,587 (including withholding taxes) as at December 31, 2023 nil three nine December 31, 2023 2022 three nine December 31, 2023 nil 2022 not (c) Long term cash bonus: According to the employment agreement with the CEO, a long-term incentive of $15 million is payable if the Company’s US market capitalization is at least $1 billion. The Company uses a risk-neutral Monte Carlo simulation to estimate the fair-value of this instrument and recognizes the incentive over the estimated period to reach the market capitalization. As at December 31, 2023 , the liability related to this long-term incentive of $ ($ as at March 31, 2023 ) is presented in Other liability in the consolidated balance sheets. During the nine December 31, 2023 , of $10,000 ( 2022 - of $65,688) was recorded in connection with the long-term incentive under selling, general and administrative expenses in the consolidated statement of loss. For the quarters ended December 31, 2023 2022 |
Note 14 - Loss Per Share
Note 14 - Loss Per Share | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 14. Loss per share: When the Company has a net loss, the effects of options, DSUs, RSUs and warrants are excluded from the calculation of diluted loss per share for periods in which a company sustains a loss. Accordingly, diluted loss per share was the same as basic loss per share because the Company has incurred losses in the periods presented. All outstanding options, DSUs, RSUs and warrants could potentially be dilutive in the future. When the Company has net income, basic net income per share using the two two may The Company’s capital structure includes securities that participate with shares on a one one two 2020 2021 January 2023 May 2023 two not not More specifically, the breakdown between participating and non-participating warrants is as follows: Reference Number of warrants outstanding Number of participating warrants Number of non-participating warrants Series A Warrants 17,858 17,858 — Series B Warrants 17,858 17,858 — Series C Warrants 43,609 43,609 — Series D Warrants 24,320 24,320 — Series E Warrants 160,429 160,429 — January 2023 Warrants 21,251 21,251 — May 2023 Warrants 303,034 303,034 — September 2023 Warrants 1,800,000 1,800,000 — Warrants classified as liability 2,388,359 2,388,359 — Warrants IFF 1,429 — 1,429 Warrants AMI 2,983 — 2,983 2020 Warrants 7,524 7,524 — 2021 Warrants 4,911 4,911 — March 2023 Warrants 2,778 — 2,778 September 2023 Pre-Funded Warrants 394,000 394,000 — MSEC Warrants 92,495 — 92,495 Warrants classified as equity 506,120 406,435 99,685 2,894,479 2,794,794 99,685 For the three nine December 31, 2023 2022 Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Recast Recast Net income (loss) attributed to equity holders $ (17,749,338 ) $ 1,288,110 $ (26,953,896 ) $ (33,893,698 ) Less: Undistributed earnings attributed to warrant holders — (620,910 ) — — Basic and dilutive income (loss) attributed to common shareholders $ (17,749,338 ) $ 667,200 $ (26,953,896 ) $ (33,893,698 ) Basic weighted-average number of common shares outstanding 4,285,229 284,619 1,784,047 237,013 Effect of dilutive securities Options, RSU's, DSU's — 71 — — Dilutive weighted-average number of common shares outstanding 4,285,229 284,690 1,784,047 237,013 Net income (loss) per share attributable to common shareholders of the Company: Basic and dilutive loss per share $ (4.14 ) $ 2.34 $ (15.11 ) $ (143.00 ) The following table summarizes outstanding securities not Three-month periods ended Nine-month periods ended Securities December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Options, RSU's, DSU's 14,075 17,062 14,075 17,133 Warrants 2,407,984 280,917 2,407,984 280,917 |
Note 15 - Fair-value Measuremen
Note 15 - Fair-value Measurements | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 15. Fair-value measurements: The Company uses various methods to estimate the fair value recognized in the consolidated financial statements. The fair value hierarchy reflects the significance of inputs used in determining the fair values: ● Level 1 ● Level 2 1 ● Level 3 not Financial assets and liabilities measured at fair value on a recurring basis are the call option granted to Neptune by Sprout's non-controlling interest owners of equity, the liability to CEO for long-term incentive, and liability related to warrants. The following table presents the Company’s hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 March 31, 2023 December 31, 2023 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 10 $ — $ — $ 911,790 $ 911,790 Other liability 13(c) – – 14,000 14,000 Total $ — $ — $ 925,790 $ 925,790 March 31, 2023 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 10 $ — $ — $ 3,156,254 $ 3,156,254 Other liability 13(c) – – 24,000 24,000 Total $ — $ — $ 3,180,254 $ 3,180,254 The liabilities related to warrants were recorded at their fair value using a Binomial pricing model. Warrants are revalued each period end at fair value through profit and loss using level 3 10 The Company has determined that the carrying values of its short-term financial assets and liabilities approximate their fair values given the short-term nature of these instruments. The carrying value of the short-term investment also approximates its fair value given the short-term maturity of the reinvested funds. For variable rate loans and borrowings, the fair value is considered to approximate the carrying amount. Sprout’s other equity interest owners granted Neptune a call option (the "Call Option") to purchase the remaining 49.9% outstanding equity interests of Sprout, at any time beginning on January 1, 2023, December 31, 2023. 3.0x 15.0x March 31, 2022, $nil March 31, 2022. 3 |
Note 16 - Commitments and Conti
Note 16 - Commitments and Contingencies | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 16. Commitments and contingencies: (a) Commitments: (i) On January 31, 2020, (ii) On March 21, 2019, February 23, 2001 December 31, 2023 March 31, 2023 9. (iii) On May 28, 2021, December 31, 2023 may three December 31, 2023 March 31, 2023 (iv) On March 16, 2021, October 21, 2022, March 16, 2023, first March 22, 2023. October 10, 2023. (v) On November 3, 2023, not June 30, 2025. (b) Contingencies: In the normal course of business, the Company is involved in various claims and legal proceedings, for which the outcomes, inflow or outflow of economic benefits, are uncertain. The most significant of which are ongoing are as follows: (i) In September 2020, May 9, 2019, April 2022 August 1- 5, 2022. June 15, 2022, one April 2021 ( June 2021). July 7, 2022, On April 13, 2023, August 23, 2023, eight September 29, 2023, not December 31, 2023 March 31, 2023 (ii) On October 22, 2020, February 4, 2024, January 15, 2024, not (iii) On February 4, 2021, not February 11, 2021, February 25, 2021, February 24, 2021, February 2021, In addition to the consumer class actions discussed above, Sprout is currently named in four June 16, 2021 two October 2023 January 9, 2023, March 3, 2023, October 1, 2021, These matters may (iv) On October 11, 2022, May 30, 2023, (v) On February 28, 2023, The outcome of these claims and legal proceedings against the Company cannot be determined with certainty and is subject to future resolution, including the uncertainties of litigation. |
Note 17 - Operating Segments
Note 17 - Operating Segments | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 17. Operating Segments: The Company measures its performance based on a single a) Geographical information: Revenue is attributed to geographical locations based on the origin of customers’ location: Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Canada $ 875,338 $ 1,347,700 $ 3,101,950 $ 7,074,759 United States 6,700,451 10,597,392 23,794,546 32,626,483 Other countries 23,963 263,816 70,961 766,736 $ 7,599,752 $ 12,208,908 $ 26,967,457 $ 40,467,978 Long-lived assets of the Company are located in the following geographical location: December 31, 2023 March 31, 2023 Canada $ 196,408 $ 250,921 United States 839,015 1,152,343 Total property, plant and equipment $ 1,035,423 $ 1,403,264 December 31, 2023 March 31, 2023 Canada $ 1,308,849 $ 1,607,089 Total intangible assets $ 1,308,849 $ 1,607,089 December 31, 2023 March 31, 2023 Canada $ 2,482,706 $ 2,426,385 Total goodwill $ 2,482,706 $ 2,426,385 b) Revenues The Company derives revenue from the sales of goods which are recognized at a point in time as follows: Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Nutraceutical products $ 2,743,019 $ 3,541,002 $ 7,984,996 $ 11,844,529 Cannabis and hemp products — 23,337 — 2,740,664 Food and beverages products 4,868,817 8,380,753 18,928,571 25,083,053 $ 7,611,836 $ 11,945,092 $ 26,913,567 $ 39,668,246 |
Note 18 - Subsequent Events
Note 18 - Subsequent Events | 9 Months Ended |
Dec. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 18. Subsequent event: On January 24, 2024, |
Insider Trading Arrangements
Insider Trading Arrangements | 9 Months Ended |
Dec. 31, 2023 | |
Insider Trading Arr Line Items | |
Material Terms of Trading Arrangement [Text Block] | 5. Not |
Rule 10b5-1 Arrangement Adopted [Flag] | false |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false |
Rule 10b5-1 Arrangement Terminated [Flag] | false |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | (a) Basis of consolidation: These condensed consolidated interim financial statements include the accounts of the Company and its subsidiaries in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated from the Company’s condensed consolidated interim financial statements. On February 10, 2021, November 3, 2023, 4 |
New Accounting Pronouncements, Policy [Policy Text Block] | (b) New standards and interpretations: New standards In October 2021, 2021 08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers 805, 2021 08 1 2 2021 08 December 15, 2022. 2021 08 April 1, 2023, In June 2016, 2016 13, 326 2016 13” 2016 13 December 15, 2019, first 2019. November 2019, No. 2019 10, 326 815 842 2019 10” two 2016 13. December 15, 2019, 2016 13, December 15, 2022. 2016 13 April 1, 2023, Accounting pronouncements not adopted No 2023 |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, 2023 March 31, 2023 Raw materials $ 5,126,337 $ 5,314,450 Work in progress 98,727 — Finished goods 4,186,124 7,360,850 Supplies and spare parts 204,984 330,774 $ 9,616,172 $ 13,006,074 |
Note 7 - Goodwill and Intangi_2
Note 7 - Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Goodwill [Table Text Block] | December 31, 2023 March 31, 2023 Biodroga $ 2,482,706 $ 2,426,385 $ 2,482,706 $ 2,426,385 |
Note 8 - Loans and Borrowings (
Note 8 - Loans and Borrowings (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Long-Term Debt Instruments [Table Text Block] | December 31, 2023 March 31, 2023 Loans and borrowings: Promissory note originally of $ 10,000,000 13,000,000 10.0 1.00 3,000,000 9,317 570,185 15.0 10.0 5.0 7.5 $ 18,092,845 $ 15,622,508 Promissory note of $ 250,000 10.0 1.00 920 75,736 291,057 218,517 Promissory notes totaling $ 550,000 10.0 1.00 3,659 96,578 624,638 496,061 Senior secured notes (the "Notes") issued by the Company on January 12, 2023 for gross proceeds of $ 4,000,000 12 16.5 6 200,000 100,000 100,000 24 713,320 850,000 338,320 — 3,607,116 Accounts receivable factoring facility contracted by Sprout on January 25, 2023, to which an inventory financing through an Invoice Purchase and Security Agreement partnership with Alterna Capital Solutions LLC, was added effective April 21, 2023. The maximum available has been amended to $ 7.5 5.0 1 8 5,258,548 2,762,110 Promissory note of $ 300,000 10.0 1.00 111,111 0.54 37,723 323,892 244,952 Accounts receivable factoring facility contracted by Biodroga on November 8, 2023 through an Invoice Purchase and Security Agreement ("PSA") partnership with Alterna Capital Solutions LLC (the "Lender"), which includes an inventory financing rider (the "Rider"). The maximum amount potentially available to be deployed by the Lender at any given time pursuant to the PSA and Rider is $ 3 1 8 1 9.5 1,393,420 — Loans and borrowings 25,984,400 22,951,264 Less current portion of loans and borrowings 25,984,400 7,538,369 Loans and borrowings, net of current portion $ — $ 15,412,895 |
Note 10 - Liability Related t_2
Note 10 - Liability Related to Warrants (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Changes in Value of Liability Related to Warrants [Table Text Block] | Warrants Amount Outstanding as at March 31, 2022 48,151 $ 5,570,530 Warrants issued during the period 257,709 14,156,571 Warrants exercised during the period (29,351 ) (1,769,000 ) Warrants reclassified to equity during the period (12,435 ) (37,710 ) Net revaluation gain (16,083,681 ) Movements in exchange rates (392,652 ) Outstanding as at December 31, 2022 264,074 $ 1,444,058 Outstanding as at March 31, 2023 285,325 $ 3,156,254 Warrants issued during the period 2,103,034 3,997,348 Net revaluation gain (6,241,812 ) Outstanding as at December 31, 2023 2,388,359 $ 911,790 |
Schedule of Outstanding Warrants [Table Text Block] | Reference Date of issuance Number of warrants outstanding Number of warrants exercisable Exercise price Expiry date Series A Warrants March 14, 2022 17,858 17,858 $ 2.50 September 26, 2028 Series B Warrants March 14, 2022 17,858 17,858 $ 2.50 September 26, 2028 Series C Warrants June 23, 2022 19,289 19,289 $ 2.50 September 26, 2028 Series C Warrants June 23, 2022 24,320 24,320 $ 2.50 June 23, 2029 Series D Warrants June 23, 2022 24,320 24,320 $ 2.50 September 26, 2028 Series E Warrants October 11, 2022 53,477 53,477 $ 64.80 October 11, 2027 Series E Warrants October 11, 2022 106,952 106,952 $ 2.50 September 26, 2028 January 2023 Warrants January 12, 2023 21,251 21,251 $ 21.20 January 12, 2028 May 2023 Warrants May 15, 2023 30,382 30,382 $ 13.20 May 15, 2028 May 2023 Warrants May 15, 2023 272,652 272,652 $ 2.50 September 26, 2028 September 2023 Warrants September 26, 2023 1,800,000 1,800,000 $ 2.50 September 26, 2028 2,388,359 2,388,359 $ 4.20 |
Warrant [Member] | |
Notes Tables | |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2020 Warrants 2021 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ — $ 309,769 $ — $ 306,704 Warrants reclassified to equity during the period — (19,058 ) — (18,652 ) Change in fair value to date of transfer to equity — (279,056 ) — (276,527 ) Translation effect — (11,655 ) — (11,525 ) Balance - end of period $ — $ — $ — $ — Series A Warrants Series B Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 106,207 $ 3,270,816 $ 3,641 $ 1,683,241 Change in fair value (99,242 ) (3,099,783 ) 3,324 (1,622,926 ) Translation effect — (136,418 ) — (59,975 ) Balance - end of period $ 6,965 $ 34,615 $ 6,965 $ 340 Series C Warrants Series D Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 494,289 $ — $ 153,598 $ — Warrants issued during the period — 4,046,836 — 3,080,121 Warrants exercised during the period — (365,224 ) — (1,403,776 ) Change in fair value (477,092 ) (3,339,370 ) (144,113 ) (1,337,675 ) Translation effect — (121,760 ) — (51,319 ) Balance - end of period $ 17,197 $ 220,482 $ 9,485 $ 287,351 Series E Warrants January 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ 2,046,082 $ — $ 352,437 $ — Warrants issued during the period — 7,029,614 — — Change in fair value (1,996,435 ) (6,128,344 ) (347,443 ) — Balance - end of period $ 49,647 $ 901,270 $ 4,994 $ — May 2023 Warrants September 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Balance - beginning of period $ — $ — $ — $ — Warrants issued during the period 2,025,247 — 1,972,101 — Change in fair value (1,910,710 ) — (1,270,101 ) — Balance - end of period $ 114,537 $ — $ 702,000 $ — |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | Series A Warrants Series B Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Share price $ 0.53 $ 12.80 $ 0.53 $ 12.80 Exercise price $ 2.50 $ 448.00 $ 2.50 $ 448.00 Dividend yield — — — — Risk-free interest 3.86 % 4.02 % 3.86 % 4.75 % Remaining contractual life (years) 4.75 4.71 4.75 0.71 Expected volatility 133.8 % 94.2 % 133.8 % 135.7 % Series C Warrants Series D Warrants December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Share price $ 0.53 $ 12.80 $ 0.53 $ 12.80 Exercise price $ 2.50 $ 92.80 $ 2.50 $ 92.80 Dividend yield — — — — Weighted average risk-free interest 3.86 % 4.05 % 3.86 % 4.58 % Weighted average remaining contractual life (years) 5.16 4.48 4.75 1.48 Weighted average expected volatility 129.8 % 94.1 % 133.8 % 112.4 % Series E Warrants January 2023 Warrants December 31, 2023 December 31, 2022 December 31, 2023 January 12, 2023 (Grant date) Share price $ 0.53 $ 12.80 $ 0.53 $ 21.20 Weighted average exercise price $ 2.50 $ 64.80 $ 2.50 $ 21.20 Dividend yield — — — — Weighted average risk-free interest 3.89 % 4.02 % 3.99 % 3.53 % Weighted average remaining contractual life (years) 4.18 4.78 4.04 5.00 Weighted average expected volatility 137.1 % 93.6 % 141.6 % 98.2 % May 2023 Warrants September 2023 Warrants December 31, 2023 May 15, 2023 (Grant date) December 31, 2023 September 26, 2023 (Grant date) Share price $ 0.53 $ 8.80 $ 0.53 $ 1.35 Exercise price $ 2.50 $ 13.20 $ 2.50 $ 2.50 Dividend yield — — — — Risk-free interest 3.87 % 3.46 % 3.86 % 4.62 % Remaining contractual life (years) 4.71 5.00 4.50 5.00 Expected volatility 134.1 % 110.9 % 133.8 % 126.8 % |
Note 11 - Capital and Other C_2
Note 11 - Capital and Other Components of Equity (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | December 31, 2023 December 31, 2022 Weighted Weighted average Number of average Number of exercise price warrants exercise price warrants Warrants outstanding at April 1, 2023 and 2022 $ 4,924.69 19,625 $ 13,013.78 4,412 Issued 0.0010 1,835,147 0.0040 16,139 Reclassification from liability related to warrants — — 3,150.0000 12,435 Exercised 0.0007 (1,348,652 ) 0.0040 (16,139 ) Warrants outstanding at December 31, 2023 and December 31, 2022 $ 190.96 506,120 $ 5,733.19 16,847 Warrants exercisable at December 31, 2023 and December 31, 2022 $ 190.96 506,120 $ 5,733.19 16,847 December 31, 2023 March 31, 2023 Number Number Number Number outstanding exercisable Amount outstanding exercisable Amount Warrants IFF (i) 1,429 1,429 $ 1,630,210 1,429 1,429 $ 1,630,210 Warrants AMI (ii) 2,983 2,983 4,449,680 2,983 2,983 4,449,680 2020 Warrants (iii) 7,524 7,524 19,058 7,524 7,524 19,058 2021 Warrants (iv) 4,911 4,911 18,652 4,911 4,911 18,652 March 2023 Warrants 2,778 2,778 37,723 2,778 2,778 37,723 September 2023 Pre-Funded Warrants 394,000 394,000 426,710 — — — MSEC Warrants 92,495 92,495 66,404 — — — 506,120 506,120 $ 6,648,437 19,625 19,625 $ 6,155,323 |
Note 12 - Non-controlling Int_2
Note 12 - Non-controlling Interest (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Equity Interest Held by Noncontrolling Interest [Table Text Block] | Name Country of incorporation December 31, 2023 March 31, 2023 Sprout United States of America 10.5 % 49.9 % |
Weighted Average Proportion of Equity Interest Held by Noncontrolling Interests [Table Text Block] | Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Sprout 23.8% 49.9% 41.2% 49.9% |
Summarized Financial Information of Noncontrolling Interest [Table Text Block] | Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Revenue from contracts with customers $ 4,868,817 $ 8,380,966 $ 18,928,571 $ 24,903,038 Cost of sales (4,347,787 ) (7,825,211 ) (18,896,730 ) (23,748,469 ) Selling, general and administrative expenses (8,327,436 ) (3,184,805 ) (16,476,345 ) (9,412,606 ) Impairment loss on goodwill and intangible assets — — — (10,164,000 ) Finance costs (1,454,080 ) (934,685 ) (4,704,644 ) (2,396,967 ) Loss before tax (9,260,486 ) (3,563,735 ) (21,149,148 ) (20,819,004 ) Income tax expense — (14,543 ) — (14,543 ) Net loss (9,260,486 ) (3,578,278 ) (21,149,148 ) (20,833,547 ) Total comprehensive loss (9,260,486 ) (3,578,278 ) (21,149,148 ) (20,833,547 ) Loss attributable to the subsidiary's non-controlling interest (1,421,144 ) (1,803,089 ) (7,353,586 ) (2,220,145 ) Comprehensive loss attributable to the subsidiary's non-controlling interest $ (1,421,144 ) $ (1,775,189 ) $ (7,353,586 ) $ (2,220,145 ) December 31, 2023 March 31, 2023 Current assets $ 7,712,019 12,382,450 Non-current assets 5,403 9,788 Current liabilities 43,561,652 12,938,219 Non-current liabilities 3,659,307 35,789,746 Total equity (deficiency) (39,503,537 ) (36,335,727 ) Attributable to: Equity holders of the Company (46,872,028 ) (20,714,912 ) Non-controlling interest $ 7,368,491 $ (15,620,815 ) Three-month period ended Nine-month period ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Cash flow provided by (used in) operating activities $ 85,994 $ (1,873,210 ) $ (2,491,563 ) $ (5,798,310 ) Cash flow provided by investing activities — — — — Cash flow provided by (used in) financing activities (409,260 ) 1,999,408 2,496,437 5,249,408 Net increase (decrease) in cash and cash equivalents $ (323,266 ) $ 126,198 $ 4,874 $ (548,902 ) |
Note 13 - Share-based Payment (
Note 13 - Share-based Payment (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | 2023 2022 Weighted Weighted average average exercise Number of exercise Number of price options price options Options outstanding at April 1st, 2023 and 2022 $ 729.32 10,443 $ 1,496.49 7,385 Granted — — 64.14 5,744 Forfeited/Cancelled 100.03 (2,978 ) 640.00 (1,650 ) Expired — — 2,028.40 (956 ) Options outstanding at December 31, 2023 and 2022 $ 975.98 7,465 $ 742.00 10,523 Options exercisable at December 31, 2023 and 2022 $ 995.86 6,971 $ 1,570.00 3,258 |
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | December 31, 2023 Options outstanding Exercisable options Weighted remaining Weighted Weighted contractual Number of number of average Exercise life options options exercise price outstanding outstanding exercisable price $62.00 - $64.00 3.63 36 12 $ 62.00 $64.01 - $242.80 3.74 2,850 2,850 65.60 $242.81 - $896.00 3.11 465 167 470.30 $896.01 - $1,129.20 2.62 2,143 2,143 1,022.00 $1,129.21 - $6,437.13 5.32 1,971 1,799 2,493.45 3.79 7,465 6,971 $ 995.86 |
Share-Based Payment Arrangement, Activity [Table Text Block] | 2023 2022 Weighted Weighted average average share Number of share Number of Notes price DSUs price DSUs DSUs outstanding at April 1, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 DSUs outstanding at December 31, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 DSUs exercisable at December 31, 2023 and 2022 $ 2,657.95 110 $ 2,657.95 110 |
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] | 2023 2022 Weighted Weighted average average share Number of share Number of Notes price RSUs price RSUs RSUs outstanding at April 1st, 2023 and 2022 $ 2,401.60 71 $ 2,389.92 626 Granted — — 132.40 10,917 Forfeited — — 770.00 (391 ) Released through the issuance of common shares 11(d) — — 224.00 (6,743 ) Withheld as payment of withholding taxes 11(d) — — 224.00 (4,338 ) RSUs outstanding at December 31, 2023 and 2022 $ 2,401.60 71 $ 2,401.60 71 RSUs exercisable at December 31, 2023 and 2022 $ 2,401.60 71 $ 2,401.60 71 |
Market Performance Options [Member] | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | 2023 2022 Weighted Weighted average average exercise Number of exercise Number of Notes price options price options Options outstanding at April 1, 2023 and 2022 $ 6,202.00 3,929 $ 6,202.00 3,929 Options outstanding at December 31, 2023 and 2022 $ 6,202.00 3,929 $ 6,202.00 3,929 Options exercisable at December 31, 2023 and 2022 $ 6,202.00 536 $ 6,202.00 536 |
Note 14 - Loss Per Share (Table
Note 14 - Loss Per Share (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Participating and Nonparticipating Warrants [Table Text Block] | Reference Number of warrants outstanding Number of participating warrants Number of non-participating warrants Series A Warrants 17,858 17,858 — Series B Warrants 17,858 17,858 — Series C Warrants 43,609 43,609 — Series D Warrants 24,320 24,320 — Series E Warrants 160,429 160,429 — January 2023 Warrants 21,251 21,251 — May 2023 Warrants 303,034 303,034 — September 2023 Warrants 1,800,000 1,800,000 — Warrants classified as liability 2,388,359 2,388,359 — Warrants IFF 1,429 — 1,429 Warrants AMI 2,983 — 2,983 2020 Warrants 7,524 7,524 — 2021 Warrants 4,911 4,911 — March 2023 Warrants 2,778 — 2,778 September 2023 Pre-Funded Warrants 394,000 394,000 — MSEC Warrants 92,495 — 92,495 Warrants classified as equity 506,120 406,435 99,685 2,894,479 2,794,794 99,685 |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Recast Recast Net income (loss) attributed to equity holders $ (17,749,338 ) $ 1,288,110 $ (26,953,896 ) $ (33,893,698 ) Less: Undistributed earnings attributed to warrant holders — (620,910 ) — — Basic and dilutive income (loss) attributed to common shareholders $ (17,749,338 ) $ 667,200 $ (26,953,896 ) $ (33,893,698 ) Basic weighted-average number of common shares outstanding 4,285,229 284,619 1,784,047 237,013 Effect of dilutive securities Options, RSU's, DSU's — 71 — — Dilutive weighted-average number of common shares outstanding 4,285,229 284,690 1,784,047 237,013 Net income (loss) per share attributable to common shareholders of the Company: Basic and dilutive loss per share $ (4.14 ) $ 2.34 $ (15.11 ) $ (143.00 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three-month periods ended Nine-month periods ended Securities December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Options, RSU's, DSU's 14,075 17,062 14,075 17,133 Warrants 2,407,984 280,917 2,407,984 280,917 |
Note 15 - Fair-value Measurem_2
Note 15 - Fair-value Measurements (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | December 31, 2023 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 10 $ — $ — $ 911,790 $ 911,790 Other liability 13(c) – – 14,000 14,000 Total $ — $ — $ 925,790 $ 925,790 March 31, 2023 Notes Level 1 Level 2 Level 3 Total Liabilities Liability related to warrants 10 $ — $ — $ 3,156,254 $ 3,156,254 Other liability 13(c) – – 24,000 24,000 Total $ — $ — $ 3,180,254 $ 3,180,254 |
Note 17 - Operating Segments (T
Note 17 - Operating Segments (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Notes Tables | |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Canada $ 875,338 $ 1,347,700 $ 3,101,950 $ 7,074,759 United States 6,700,451 10,597,392 23,794,546 32,626,483 Other countries 23,963 263,816 70,961 766,736 $ 7,599,752 $ 12,208,908 $ 26,967,457 $ 40,467,978 |
Long-Lived Assets by Geographic Areas [Table Text Block] | December 31, 2023 March 31, 2023 Canada $ 196,408 $ 250,921 United States 839,015 1,152,343 Total property, plant and equipment $ 1,035,423 $ 1,403,264 December 31, 2023 March 31, 2023 Canada $ 1,308,849 $ 1,607,089 Total intangible assets $ 1,308,849 $ 1,607,089 December 31, 2023 March 31, 2023 Canada $ 2,482,706 $ 2,426,385 Total goodwill $ 2,482,706 $ 2,426,385 |
Disaggregation of Revenue [Table Text Block] | Three-month periods ended Nine-month periods ended December 31, 2023 December 31, 2022 December 31, 2023 December 31, 2022 Nutraceutical products $ 2,743,019 $ 3,541,002 $ 7,984,996 $ 11,844,529 Cannabis and hemp products — 23,337 — 2,740,664 Food and beverages products 4,868,817 8,380,753 18,928,571 25,083,053 $ 7,611,836 $ 11,945,092 $ 26,913,567 $ 39,668,246 |
Note 1 - Reporting Entity (Deta
Note 1 - Reporting Entity (Details Textual) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||
Nov. 20, 2023 USD ($) shares | Sep. 07, 2023 shares | Jun. 09, 2022 shares | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) | Mar. 31, 2023 USD ($) shares | Nov. 03, 2023 | Sep. 30, 2023 | Sep. 08, 2023 shares | Aug. 17, 2023 | Jun. 13, 2022 shares | Feb. 10, 2021 | |
Common Stock, Shares, Outstanding (in shares) | shares | 24,100,000 | 198,000,000 | 4,532,038 | 4,532,038 | 300,070 | 600,000 | 5,700,000 | |||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $ (19,170,482) | $ (497,451) | $ (34,307,482) | $ (44,289,638) | $ (88,800,000) | |||||||||
Net Cash Provided by (Used in) Operating Activities | (7,565,123) | $ (20,669,892) | (28,600,000) | |||||||||||
Retained Earnings (Accumulated Deficit) | $ (410,595,259) | $ (410,595,259) | $ (383,641,363) | |||||||||||
Reverse Stock Split [Member] | ||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 40 | 35 | ||||||||||||
Datasys Acquisition [Member] | ||||||||||||||
Business Combination, Consideration Transferred | $ 112,000,000 | |||||||||||||
Payments to Acquire Businesses, Gross | 20,000,000 | |||||||||||||
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $ 32,000,000 | |||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares | 10,000,000 | |||||||||||||
Datasys Acquisition [Member] | Earn Out [Member] | ||||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low | $ 5,000,000 | |||||||||||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 22,000,000 | |||||||||||||
Datasys Acquisition [Member] | Earn Out [Member] | Minimum [Member] | ||||||||||||||
Business Combination, Contingent Consideration, EBITDA Threshold | 13,000,000 | |||||||||||||
Datasys Acquisition [Member] | Earn Out [Member] | Maximum [Member] | ||||||||||||||
Business Combination, Contingent Consideration, EBITDA Threshold | $ 16,000,000 | |||||||||||||
Datasys Acquisition [Member] | Paid in Kind Seller Note [Member] | ||||||||||||||
Debt Instrument, Term (Year) | 5 years | |||||||||||||
Debt Instrument, Face Amount | $ 31,000,000 | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7% | |||||||||||||
Debt Instrument, Early Repayment Discount Percentage | 25% | |||||||||||||
Sprout Foods, Inc. [Member] | ||||||||||||||
Subsidiary, Ownership Percentage, Parent | 10.50% | 10.50% | 49.90% | 89.50% | 50.10% | 89.50% | 50.10% |
Note 3 - Significant Accounti_2
Note 3 - Significant Accounting Policies (Details Textual) | Dec. 31, 2023 | Nov. 03, 2023 | Sep. 30, 2023 | Aug. 17, 2023 | Mar. 31, 2023 | Feb. 10, 2021 |
Sprout Foods, Inc. [Member] | ||||||
Subsidiary, Ownership Percentage, Parent | 10.50% | 89.50% | 50.10% | 89.50% | 49.90% | 50.10% |
Note 4 - Business Combination_2
Note 4 - Business Combination and Disposal (Details Textual) | 3 Months Ended | 5 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||
Nov. 03, 2023 USD ($) | Nov. 09, 2022 USD ($) | Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Nov. 09, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2023 | Sep. 18, 2023 | Aug. 17, 2023 | Jan. 01, 2023 | Nov. 09, 2022 CAD ($) | Feb. 10, 2022 USD ($) | Feb. 11, 2021 | Feb. 10, 2021 | |
Unrealized Gain (Loss) on Derivatives | $ 1,596,901 | $ 8,367,871 | $ 7,186,846 | $ 16,083,681 | |||||||||||||
Restructuring Costs | $ 2,066,405 | ||||||||||||||||
Sprout Foods, Inc. [Member] | |||||||||||||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 49.90% | ||||||||||||||||
Subsidiary, Ownership Percentage, Parent | 89.50% | 10.50% | 10.50% | 49.90% | 50.10% | 89.50% | 50.10% | ||||||||||
Sprout Foods, Inc. [Member] | Minimum [Member] | |||||||||||||||||
Equity Interest, Retained Interest | 10% | ||||||||||||||||
Sprout Foods, Inc. [Member] | Maximum [Member] | |||||||||||||||||
Equity Interest, Retained Interest | 15% | ||||||||||||||||
Sprout Foods, Inc. [Member] | |||||||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 50.10% | 50.10% | |||||||||||||||
Derivative Asset | $ 0 | $ 0 | $ 0 | $ 5,523,255 | |||||||||||||
Derivative Asset, Measurement Input | 0 | ||||||||||||||||
Unrealized Gain (Loss) on Derivatives | $ (5,598,198) | $ 0 | $ (5,598,198) | ||||||||||||||
Sprout Foods, Inc. [Member] | Measurement Input, Discount Rate [Member] | |||||||||||||||||
Derivative Asset, Measurement Input | 0.089 | ||||||||||||||||
Sprout Foods, Inc. [Member] | Measurement Input, Revenue Multiple [Member] | |||||||||||||||||
Derivative Asset, Measurement Input | 2.3 | 3 | |||||||||||||||
Sprout Foods, Inc. [Member] | Measurement Input, EBITDA Multiple [Member] | |||||||||||||||||
Derivative Asset, Measurement Input | 12 | 15 | |||||||||||||||
Sprout Foods, Inc. [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||||||||||||||||
Derivative Asset, Measurement Input | 0.20 | 0.50 | |||||||||||||||
Discontinued Operations, Disposed of by Sale [Member] | Canadian Cannabis Business [Member] | |||||||||||||||||
Disposal Group, Including Discontinued Operation, Consideration | $ 3,790,340 | $ 3,790,340 | $ 5,150,000 | ||||||||||||||
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax | (586,783) | ||||||||||||||||
Disposal Group, Including Discontinued Operation, Assets | 3,203,557 | $ 3,203,557 | |||||||||||||||
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down | $ 15,346,119 |
Note 5 - Inventories (Details T
Note 5 - Inventories (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Inventory Write-down | $ 0 | $ 0 | $ 216,184 | $ 3,079,997 |
Note 5 - Inventories - Schedule
Note 5 - Inventories - Schedule of Inventories (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Raw materials | $ 5,126,337 | $ 5,314,450 |
Work in progress | 98,727 | 0 |
Finished goods | 4,186,124 | 7,360,850 |
Supplies and spare parts | 204,984 | 330,774 |
Inventory, Net | $ 9,616,172 | $ 13,006,074 |
Note 6 - Property, Plant and _2
Note 6 - Property, Plant and Equipment (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | |
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent | $ 3,203,557 | |||||
Impairment of Long-Lived Assets to be Disposed of | $ 0 | $ 0 | $ 0 | $ 0 | $ 15,346,119 |
Note 7 - Goodwill and Intangi_3
Note 7 - Goodwill and Intangible Assets (Details Textual) | 3 Months Ended | 9 Months Ended | ||||
Dec. 31, 2023 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Goodwill, Impairment Loss | $ 0 | $ 0 | $ 0 | $ 7,570,471 | ||
Goodwill | 2,482,706 | $ 2,426,385 | 2,482,706 | |||
Impairment of Intangible Assets, Finite-Lived | $ 0 | 0 | $ 0 | $ 2,593,529 | ||
Sprout Foods, Inc. [Member] | ||||||
Goodwill, Impairment Loss | 11,971,965 | $ 0 | $ 7,570,471 | |||
Goodwill | 0 | |||||
Sprout Foods, Inc. [Member] | Trademarks [Member] | ||||||
Impairment of Intangible Assets, Finite-Lived | $ 15,385,531 | $ 2,593,529 | ||||
Sprout Foods, Inc. [Member] | Measurement Input, Discount Rate [Member] | ||||||
Reporting Unit, Measurement Input | 0.116 | |||||
Sprout Foods, Inc. [Member] | Measurement Input, Long-Term Revenue Growth Rate [Member] | ||||||
Reporting Unit, Measurement Input | 2.5 | 2.5 | ||||
Biodroga Nutraceuticals Inc. [Member] | ||||||
Goodwill, Impairment Loss | $ 0 | |||||
Goodwill | $ 2,482,706 | $ 2,426,385 | $ 2,482,706 |
Note 7 - Goodwill and Intangi_4
Note 7 - Goodwill and Intangible Assets - Goodwill Allocated to Each Reporting Unit (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Goodwill | $ 2,482,706 | $ 2,426,385 |
Biodroga Nutraceuticals Inc. [Member] | ||
Goodwill | $ 2,482,706 | $ 2,426,385 |
Note 8 - Loans and Borrowings_2
Note 8 - Loans and Borrowings (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||||||||||||||||||||
Nov. 17, 2023 | Oct. 13, 2023 | Aug. 22, 2023 | May 22, 2023 | Jan. 12, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Jan. 01, 2024 | Nov. 06, 2023 | Nov. 03, 2023 | Sep. 30, 2023 | Aug. 17, 2023 | May 10, 2023 | Apr. 27, 2023 | Apr. 20, 2023 | Mar. 31, 2023 | Jan. 25, 2023 | Jul. 13, 2022 | Jul. 12, 2022 | Feb. 10, 2021 | |
Repayments of Long-Term Debt | $ 30,921,043 | $ 0 | ||||||||||||||||||||
Interest Expense, Debt | $ 876,436 | $ 311,679 | 4,116,994 | 786,311 | ||||||||||||||||||
Payment for Debt Extinguishment or Debt Prepayment Cost | 278,386 | 655,132 | ||||||||||||||||||||
Payments of Debt Restructuring Costs | $ 0 | $ 0 | $ 138,606 | $ 0 | ||||||||||||||||||
Sprout Foods, Inc. [Member] | ||||||||||||||||||||||
Subsidiary, Ownership Percentage, Parent | 10.50% | 10.50% | 89.50% | 50.10% | 89.50% | 49.90% | 50.10% | |||||||||||||||
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | ||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 5,000,000 | $ 5,000,000 | $ 7,500,000 | $ 7,500,000 | $ 5,000,000 | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | 8% | ||||||||||||||||||||
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 10% | 15% | 15% | 10% | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Kind | 10% | 10% | 10% | 7.50% | ||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Cash | 15% | 15% | 5% | 7.50% | ||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Hereto Rate | 5% | |||||||||||||||||||||
Debt Instrument, Face Amount | $ 13,000,000 | $ 13,000,000 | $ 10,000,000 | |||||||||||||||||||
Note Purchase Agreement [Member] | CCUR Holdings, Inc. [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 24% | 16.50% | 24% | 24% | ||||||||||||||||||
Debt Instrument, Term (Year) | 12 years | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Kind | 6% | |||||||||||||||||||||
Repayments of Long-Term Debt | $ 2,300,000 | $ 1,000,000 | ||||||||||||||||||||
Debt Instrument, Face Amount | $ 4,000,000 | |||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 1,000,000 | 2,000,000 | ||||||||||||||||||||
Debt Instrument, Extension Period, After Registration Form Filed (Day) | 30 days | |||||||||||||||||||||
Debt Instrument, Fee Amount | $ 138,606 | $ 200,000 | $ 100,000 | $ 100,000 | ||||||||||||||||||
Biodroga Nutraceuticals Inc. [Member] | Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | ||||||||||||||||||||||
Debt Instrument, Collateral, Percentage of Inventory | 75% | |||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | 3,000,000 | 3,000,000 | |||||||||||||||||||
Debt Instrument, Incremental Maximum Increase | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||||||||||||
Line of Credit Facility, Maximum Overadvance | $ 8,000,000 | $ 8,000,000 | $ 8,000,000 | |||||||||||||||||||
Debt Instrument, Usage Fee Percentage | 1% | |||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | 9.50% | ||||||||||||||||||||
Debt Instrument, Term (Year) | 12 months | |||||||||||||||||||||
Biodroga Nutraceuticals Inc. [Member] | Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | Minimum [Member] | ||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% |
Note 8 - Loans and Borrowings -
Note 8 - Loans and Borrowings - Schedule of Loans and Borrowings (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Loans and borrowings | $ 25,984,400 | $ 22,951,264 |
Less current portion of loans and borrowings | 25,984,400 | 7,538,369 |
Loans and borrowings, net of current portion | 0 | 15,412,895 |
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | ||
Loans and borrowings | 18,092,845 | 15,622,508 |
Secured Promissory Note Issued August 26, 2022 [Member] | ||
Loans and borrowings | 291,057 | 218,517 |
Secured Promissory Note Issued November 8, 2022 [Member] | ||
Loans and borrowings | 624,638 | 496,061 |
Note Purchase Agreement [Member] | CCUR Holdings, Inc. [Member] | ||
Loans and borrowings | 0 | 3,607,116 |
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | ||
Loans and borrowings | 5,258,548 | 2,762,110 |
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | Biodroga Nutraceuticals Inc. [Member] | ||
Loans and borrowings | 1,393,420 | 0 |
Secured Promissory Note Issued March 11, 2023 [Member] | ||
Loans and borrowings | $ 323,892 | $ 244,952 |
Note 8 - Loans and Borrowings_3
Note 8 - Loans and Borrowings - Schedule of Loans and Borrowings (Details) (Parentheticals) - USD ($) | 9 Months Ended | 12 Months Ended | |||||||||||||||
Nov. 17, 2023 | Feb. 15, 2023 | Jan. 12, 2023 | Sep. 09, 2022 | Jul. 13, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Jan. 24, 2024 | Jan. 01, 2024 | Nov. 06, 2023 | May 22, 2023 | May 10, 2023 | Apr. 27, 2023 | Apr. 20, 2023 | Jan. 25, 2023 | Jul. 12, 2022 | |
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 645,921 | ||||||||||||||||
Proceeds from Issuance of Long-Term Debt | $ 30,917,703 | $ 3,800,000 | |||||||||||||||
Warrants issued, value | 6,648,437 | $ 6,155,323 | |||||||||||||||
Warrants and Rights Outstanding | $ 6,648,437 | $ 6,155,323 | |||||||||||||||
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 13,000,000 | $ 13,000,000 | $ 10,000,000 | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | 10% | 15% | 15% | |||||||||||||
Interest increase | 1% | 1% | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Cash | 15% | 5% | 7.50% | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Kind | 10% | 10% | 7.50% | ||||||||||||||
Proceeds from Issuance of Long-Term Debt | 3,000,000 | $ 3,000,000 | $ 3,000,000 | ||||||||||||||
Face amount | $ 13,000,000 | $ 13,000,000 | $ 10,000,000 | ||||||||||||||
Interest | 10% | 10% | 15% | 15% | |||||||||||||
Interest, payable in kind, term | 10% | 10% | 7.50% | ||||||||||||||
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | Subsequent Event [Member] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Cash | 5% | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Kind | 7.50% | ||||||||||||||||
Interest, payable in kind, term | 7.50% | ||||||||||||||||
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 9,317 | 9,317 | 9,317 | ||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 570,185 | $ 570,185 | $ 570,185 | ||||||||||||||
Secured Promissory Note Issued August 26, 2022 [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 250,000 | $ 250,000 | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||||||||||||||
Interest increase | 1% | ||||||||||||||||
Face amount | $ 250,000 | $ 250,000 | |||||||||||||||
Interest | 10% | ||||||||||||||||
Secured Promissory Note Issued August 26, 2022 [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 920 | 920 | |||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 75,736 | $ 75,736 | |||||||||||||||
Secured Promissory Note Issued November 8, 2022 [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 550,000 | $ 550,000 | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||||||||||||||
Interest increase | 1% | ||||||||||||||||
Face amount | $ 550,000 | $ 550,000 | |||||||||||||||
Interest | 10% | ||||||||||||||||
Secured Promissory Note Issued November 8, 2022 [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 3,659 | 3,659 | |||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 96,578 | $ 96,578 | |||||||||||||||
Note Purchase Agreement [Member] | CCUR Holdings, Inc. [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 4,000,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 16.50% | 24% | 24% | ||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage, Payable in Kind | 6% | ||||||||||||||||
Proceeds from Issuance of Long-Term Debt | $ 4,000,000 | ||||||||||||||||
Face amount | $ 4,000,000 | ||||||||||||||||
Term (Year) | 12 years | ||||||||||||||||
Interest | 16.50% | 24% | 24% | ||||||||||||||
Interest, payable in kind, term | 6% | ||||||||||||||||
Exit fee | $ 200,000 | $ 100,000 | $ 138,606 | ||||||||||||||
Debt issuance cost | $ 713,320 | ||||||||||||||||
Warrants issued (in shares) | 850,000 | ||||||||||||||||
Warrants issued, value | $ 338,320 | ||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 850,000 | ||||||||||||||||
Warrants and Rights Outstanding | $ 338,320 | ||||||||||||||||
Note Purchase Agreement [Member] | CCUR Holdings, Inc. [Member] | Forecast [Member] | |||||||||||||||||
Exit fee | $ 100,000 | ||||||||||||||||
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8% | ||||||||||||||||
Interest | 8% | ||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 5,000,000 | $ 7,500,000 | $ 7,500,000 | $ 5,000,000 | |||||||||||||
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | Biodroga Nutraceuticals Inc. [Member] | |||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | ||||||||||||||||
Term (Year) | 12 months | ||||||||||||||||
Interest | 9.50% | ||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 3,000,000 | $ 3,000,000 | |||||||||||||||
Interest, basis spread | 1% | ||||||||||||||||
Debt Instrument, Incremental Maximum Increase | 1,000,000 | $ 1,000,000 | |||||||||||||||
Line of Credit Facility, Maximum Overadvance | $ 8,000,000 | $ 8,000,000 | |||||||||||||||
Invoice Purchase and Security Agreement [Member] | Alterna Capital Solutions LLC [Member] | Prime Rate [Member] | |||||||||||||||||
Interest, basis spread | 1% | ||||||||||||||||
Secured Promissory Note Issued March 11, 2023 [Member] | |||||||||||||||||
Debt Instrument, Face Amount | $ 300,000 | ||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10% | ||||||||||||||||
Interest increase | 1% | ||||||||||||||||
Face amount | $ 300,000 | ||||||||||||||||
Interest | 10% | ||||||||||||||||
Warrants issued (in shares) | 111,111 | ||||||||||||||||
Warrants issued, value | $ 37,723 | ||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 111,111 | ||||||||||||||||
Warrants issued, exercise price (in dollars per share) | $ 0.54 | ||||||||||||||||
Warrants and Rights Outstanding | $ 37,723 |
Note 9 - Provisions (Details Te
Note 9 - Provisions (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||
Dec. 11, 2023 | Oct. 10, 2023 | Aug. 23, 2023 | Mar. 22, 2023 | Oct. 21, 2022 | Jul. 07, 2022 | Mar. 23, 2022 | Aug. 10, 2020 | Dec. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2019 | Mar. 21, 2019 | |
Stock Issued During Period, Value, Litigation Settlement | $ 2,750,000 | |||||||||||||||
Other Legal Fees Obligations [Member] | ||||||||||||||||
Loss Contingency Accrual | 2,514,862 | $ 2,514,862 | $ 1,384,532 | |||||||||||||
Claims Made Regarding Certain Royalty Payments by Former CEO[Member] | ||||||||||||||||
Percentage of Royalties Payable | 1% | 1% | ||||||||||||||
Loss Contingency Accrual | 1,137,882 | 1,137,882 | 963,808 | |||||||||||||
Loss Contingency Accrual, Period Increase (Decrease) | 76,072 | 174,074 | ||||||||||||||
Loss Contingency Accrual, Payments | $ 64,415 | 0 | $ 281,244 | |||||||||||||
Loss Contingency Accrual, Foreign Currency Translation Adjustment | $ 9,317 | $ 37,707 | ||||||||||||||
Claim and Demand For Arbitration Against Peter M. Galloway and PMGSL Holdings, LLC [Member] | ||||||||||||||||
Loss Contingency Accrual | 4,157,014 | 4,157,014 | 600,000 | |||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,000,000 | $ 68,000 | ||||||||||||||
Litigation Settlement, Amount Awarded to Other Party, Before Fees | $ 2,200,000 | |||||||||||||||
Litigation Settlement, Amount Awarded to Other Party, Interest Rate | 10.50% | |||||||||||||||
Lawsuit Against 9354-7537 Quebec Inc. for Alleged Breach of Supply Agreement [Member] | ||||||||||||||||
Loss Contingency Accrual | 0 | 0 | ||||||||||||||
Loss Contingency Accrual, Foreign Currency Translation Adjustment | (63,381) | |||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 1,127,024 | $ 543,774 | ||||||||||||||
Gain (Loss) Related to Litigation Settlement | $ 583,430 | |||||||||||||||
Payments for Legal Settlements | 515,464 | |||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | ||||||||||||||||
Loss Contingency Accrual | $ 0 | 0 | ||||||||||||||
Payments for Legal Settlements | $ 1,500,000 | |||||||||||||||
Loss Contingency, Damages Paid, Value | $ 500,000 | |||||||||||||||
Loss Contingency, Damages Paid, Value, Per Installment | $ 500,000 | |||||||||||||||
Stock Issued During Period, Shares, Litigation Settlement (in shares) | 2,522,936 | |||||||||||||||
Stock Issued During Period, Value, Litigation Settlement | $ 2,750,000 | |||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | Minimum [Member] | ||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,000,000 | |||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | Maximum [Member] | ||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,250,000 | |||||||||||||||
Carolina Rework Solutions, LLC v, Neptune Health & Wellness Innovation, Inc. [Member] | ||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 2,000,000 | 2,000,000 | 315,909 | |||||||||||||
Baxter Food Group Limited Litigation [Member] | ||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 5,000,000 | $ 5,000,000 | $ 0 |
Note 10 - Liability Related t_3
Note 10 - Liability Related to Warrants (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Sep. 26, 2023 | May 15, 2023 | May 15, 2023 | May 11, 2023 | Mar. 15, 2023 | Jan. 12, 2023 | Oct. 11, 2022 | Oct. 06, 2022 | Jun. 24, 2022 | Jun. 23, 2022 | Aug. 31, 2022 | Dec. 31, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Sep. 25, 2023 | Mar. 14, 2023 | Mar. 31, 2022 | |
Payments of Stock Issuance Costs | $ 1,521,640 | $ 1,330,211 | ||||||||||||||||||
Finance Costs | $ 1,602,981 | $ 1,362,776 | 6,570,787 | 2,658,305 | ||||||||||||||||
Unrealized Gain (Loss) on Derivatives | 1,596,901 | $ 8,367,871 | 7,186,846 | 16,083,681 | ||||||||||||||||
Proceeds from Issuance of Long-Term Debt | 30,917,703 | $ 3,800,000 | ||||||||||||||||||
Warrants and Rights Outstanding | 6,648,437 | $ 6,648,437 | $ 6,155,323 | |||||||||||||||||
CCUR Holdings, Inc. [Member] | Note Purchase Agreement [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 850,000 | |||||||||||||||||||
Proceeds from Issuance of Long-Term Debt | $ 4,000,000 | |||||||||||||||||||
Warrants and Rights Outstanding | $ 338,320 | $ 338,320 | ||||||||||||||||||
Long-Term Debt, Fair Value | $ 3,661,680 | |||||||||||||||||||
Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,835,147 | 16,139 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 190.96 | $ 5,733.19 | $ 190.96 | $ 5,733.19 | $ 4,924.69 | $ 13,013.78 | ||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 1,348,652 | 16,139 | ||||||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in shares) | 0.0007 | 0.004 | ||||||||||||||||||
September 2023 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,800,000 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | |||||||||||||||||||
Proceeds from Issuance of Warrants | $ 1,972,101 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,800,000 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
September 2023 Pre-Funded Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 1,550,000 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0001 | |||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 1,156,000 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 394,000 | |||||||||||||||||||
Proceeds from Issuance of Warrants | $ 2,021,466 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 116 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,550,000 | |||||||||||||||||||
Warrants and Rights Outstanding | $ 394,000 | $ 394,000 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Modified Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 478,132 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Modified Warrants [Member] | Minimum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 13.2 | |||||||||||||||||||
Modified Warrants [Member] | Maximum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3,150 | |||||||||||||||||||
Warrants Expiring June 23, 2029 [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 24,320 | 24,320 | 24,320 | |||||||||||||||||
Warrants Issued in May 2023 Direct Offering [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 303,032 | 303,032 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | $ 13.2 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||
Pre-Funded Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 192,652 | 16,140 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.004 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 192,652 | |||||||||||||||||||
Proceeds from Issuance of Warrants | $ 1,255,240 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 65 | $ 541 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 16,140 | 0 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
May 2023 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 13.2 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | |||||||||||||||||||
Proceeds from Issuance of Warrants | $ 2,025,247 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 303,032 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Warrants Issued in March 2022, June 2022, and October 2022 [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 13.2 | $ 13.2 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 210,597 | 210,597 | ||||||||||||||||||
Unrealized Gain (Loss) on Derivatives | $ (787,985) | |||||||||||||||||||
Warrants Issued in March 2022, June 2022, and October 2022 [Member] | Minimum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 64.8 | |||||||||||||||||||
Warrants Issued in March 2022, June 2022, and October 2022 [Member] | Maximum [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 448 | |||||||||||||||||||
January 2023 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 21,250 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 21.2 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Warrants and Rights Outstanding | $ 338,320 | |||||||||||||||||||
Series E Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 160,428 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | $ 13.2 | $ 13.2 | $ 64.8 | ||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 106,952 | 106,952 | ||||||||||||||||||
Unrealized Gain (Loss) on Derivatives | $ 1,029,614 | |||||||||||||||||||
Derivative Liability | $ 7,029,614 | |||||||||||||||||||
Series C Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 48,640 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 5,031 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 43,609 | 24,320 | 48,640 | |||||||||||||||||
Derivative Liability | $ 4,046,836 | |||||||||||||||||||
Class of Warrant or Right, Extension Term (Year) | 2 years | |||||||||||||||||||
Series D Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 48,640 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 24,320 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 24,320 | 48,640 | ||||||||||||||||||
Derivative Liability | $ 3,080,121 | |||||||||||||||||||
June 2022 Common Warrant [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | $ 13.2 | $ 13.2 | $ 92.8 | ||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 384,446 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 1,769,000 | |||||||||||||||||||
Unrealized Gain (Loss) on Derivatives | $ (2,126,955) | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in shares) | 92.8 | |||||||||||||||||||
Series C and Series D Warrants [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 9,613 | |||||||||||||||||||
Proceeds from Warrant Exercises | $ 1,769,000 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in shares) | 92.8 | |||||||||||||||||||
September 2023 Direct Offering [Member] | ||||||||||||||||||||
Stock and Stock Equivalents Issued During Period, Shares, New Issues (in shares) | 1,800,000 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 2.5 | |||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 4,500,000 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 250,000 | |||||||||||||||||||
Proceeds from Issuance of Common Stock | $ 506,278 | |||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 763,012 | |||||||||||||||||||
Payments of Stock Issuance Costs | 85,847 | |||||||||||||||||||
Finance Costs | 334,397 | |||||||||||||||||||
September 2023 Direct Offering [Member] | Warrants [Member] | ||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 342,768 | |||||||||||||||||||
May 2023 Direct Offering [Member] | ||||||||||||||||||||
Stock and Stock Equivalents Issued During Period, Shares, New Issues (in shares) | 303,032 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 13.2 | $ 13.2 | $ 13.2 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 4,000,000 | $ 4,000,000 | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 110,380 | 110,380 | ||||||||||||||||||
Proceeds from Issuance of Common Stock | 719,513 | |||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 758,628 | |||||||||||||||||||
Payments of Stock Issuance Costs | 136,461 | |||||||||||||||||||
Finance Costs | 384,102 | |||||||||||||||||||
May 2023 Direct Offering [Member] | Warrants [Member] | ||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 238,065 | |||||||||||||||||||
October 2022 Direct Offering [Member] | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 74.8 | |||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 5,135,002 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 80,214 | |||||||||||||||||||
Payments of Stock Issuance Costs | $ 0 | |||||||||||||||||||
Finance Costs | $ 865,000 | |||||||||||||||||||
Number of Shares Per Unit Issued (in shares) | 1 | |||||||||||||||||||
Number of Warrants Per Unit (in shares) | 1 | |||||||||||||||||||
Proceeds From Issuance or Sale of Equity, Gross | $ 6,000,002 | |||||||||||||||||||
June 2022 Direct Offering [Member] | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 102.8 | |||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 5,000,002 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 32,500 | |||||||||||||||||||
Payments of Stock Issuance Costs | $ 0 | |||||||||||||||||||
Finance Costs | $ 465,211 | |||||||||||||||||||
Legal Fees | $ 170,739 |
Note 10 - Liability Related t_4
Note 10 - Liability Related to Warrants - Change in Value of Liability Related to Warrants (Details) - USD ($) | 9 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Outstanding, number (in shares) | 2,894,479 | |
Warrant [Member] | ||
Outstanding, number (in shares) | 285,325 | 48,151 |
Balance | $ 3,156,254 | $ 5,570,530 |
Warrants issued (in shares) | 2,103,034 | 257,709 |
Warrants issued during the period | $ 3,997,348 | $ 14,156,571 |
Warrants exercised during the period (in shares) | (29,351) | |
Warrants exercised during the period | $ (1,769,000) | |
Warrants reclassified to equity during the period (in shares) | (12,435) | |
Warrants reclassified to equity during the period | $ (37,710) | |
Net revaluation gain | $ (6,241,812) | (16,083,681) |
Movements in exchange rates | $ (392,652) | |
Outstanding, number (in shares) | 2,388,359 | 264,074 |
Balance | $ 911,790 | $ 1,444,058 |
Note 10 - Liability Related t_5
Note 10 - Liability Related to Warrants - Outstanding Warrants (Details) - $ / shares | Dec. 31, 2023 | Sep. 26, 2023 | Mar. 31, 2023 | Mar. 15, 2023 | Jan. 12, 2023 | Dec. 31, 2022 | Mar. 31, 2022 |
Number of warrants outstanding (in shares) | 2,894,479 | ||||||
January 2023 Warrants [Member] | |||||||
Exercise price (in dollars per share) | $ 21.2 | ||||||
May 2023 Warrants [Member] | |||||||
Exercise price (in dollars per share) | $ 13.2 | ||||||
September 2023 Warrants [Member] | |||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Warrant [Member] | |||||||
Number of warrants outstanding (in shares) | 2,388,359 | 285,325 | 264,074 | 48,151 | |||
Number of warrants exercisable (in shares) | 2,388,359 | ||||||
Exercise price (in dollars per share) | $ 4.2 | ||||||
Warrant [Member] | Series A Warrants [Member] | |||||||
Date of issuance | Mar. 14, 2022 | ||||||
Number of warrants outstanding (in shares) | 17,858 | ||||||
Number of warrants exercisable (in shares) | 17,858 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | Series B Warrants [Member] | |||||||
Date of issuance | Mar. 14, 2022 | ||||||
Number of warrants outstanding (in shares) | 17,858 | ||||||
Number of warrants exercisable (in shares) | 17,858 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | Series C Warrants, 1 [Member] | |||||||
Date of issuance | Jun. 23, 2022 | ||||||
Number of warrants outstanding (in shares) | 19,289 | ||||||
Number of warrants exercisable (in shares) | 19,289 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | Series C Warrants, 2 [Member] | |||||||
Date of issuance | Jun. 23, 2022 | ||||||
Number of warrants outstanding (in shares) | 24,320 | ||||||
Number of warrants exercisable (in shares) | 24,320 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Jun. 23, 2029 | ||||||
Warrant [Member] | Series D Warrants [Member] | |||||||
Date of issuance | Jun. 23, 2022 | ||||||
Number of warrants outstanding (in shares) | 24,320 | ||||||
Number of warrants exercisable (in shares) | 24,320 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | Series E Warrants, 1 [Member] | |||||||
Date of issuance | Oct. 11, 2022 | ||||||
Number of warrants outstanding (in shares) | 53,477 | ||||||
Number of warrants exercisable (in shares) | 53,477 | ||||||
Exercise price (in dollars per share) | $ 64.8 | ||||||
Expiry date | Oct. 11, 2027 | ||||||
Warrant [Member] | Series E Warrants, 2 [Member] | |||||||
Date of issuance | Oct. 11, 2022 | ||||||
Number of warrants outstanding (in shares) | 106,952 | ||||||
Number of warrants exercisable (in shares) | 106,952 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | January 2023 Warrants [Member] | |||||||
Date of issuance | Jan. 12, 2023 | ||||||
Number of warrants outstanding (in shares) | 21,251 | ||||||
Number of warrants exercisable (in shares) | 21,251 | ||||||
Exercise price (in dollars per share) | $ 21.2 | ||||||
Expiry date | Jan. 12, 2028 | ||||||
Warrant [Member] | May 2023 Warrants [Member] | |||||||
Date of issuance | May 15, 2023 | ||||||
Number of warrants outstanding (in shares) | 30,382 | ||||||
Number of warrants exercisable (in shares) | 30,382 | ||||||
Exercise price (in dollars per share) | $ 13.2 | ||||||
Expiry date | May 15, 2028 | ||||||
Warrant [Member] | May 2023 Warrants 3 [Member] | |||||||
Date of issuance | May 15, 2023 | ||||||
Number of warrants outstanding (in shares) | 272,652 | ||||||
Number of warrants exercisable (in shares) | 272,652 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 | ||||||
Warrant [Member] | September 2023 Warrants [Member] | |||||||
Date of issuance | Sep. 26, 2023 | ||||||
Number of warrants outstanding (in shares) | 1,800,000 | ||||||
Number of warrants exercisable (in shares) | 1,800,000 | ||||||
Exercise price (in dollars per share) | $ 2.5 | ||||||
Expiry date | Sep. 26, 2028 |
Note 10 - Liability Related t_6
Note 10 - Liability Related to Warrants - Changes in Fair Value (Details) - Warrant [Member] - USD ($) | 9 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Balance | $ 3,156,254 | $ 5,570,530 |
Warrants reclassified to equity during the period | 6,241,812 | 16,083,681 |
Change in fair value to date of transfer to equity | 37,710 | |
Movements in exchange rates | (392,652) | |
Balance | 911,790 | 1,444,058 |
Net revaluation gain | (6,241,812) | (16,083,681) |
Warrants issued during the period | 3,997,348 | 14,156,571 |
The 2020 Warrants [Member] | ||
Balance | 0 | 309,769 |
Warrants reclassified to equity during the period | 0 | (19,058) |
Change in fair value to date of transfer to equity | 0 | (279,056) |
Movements in exchange rates | 0 | (11,655) |
Balance | 0 | 0 |
Net revaluation gain | 0 | 19,058 |
Series A Warrants [Member] | ||
Balance | 106,207 | 3,270,816 |
Warrants reclassified to equity during the period | 99,242 | 3,099,783 |
Movements in exchange rates | 0 | (136,418) |
Balance | 6,965 | 34,615 |
Net revaluation gain | (99,242) | (3,099,783) |
Series C Warrants [Member] | ||
Balance | 494,289 | 0 |
Warrants reclassified to equity during the period | 477,092 | 3,339,370 |
Movements in exchange rates | 0 | (121,760) |
Balance | 17,197 | 220,482 |
Net revaluation gain | (477,092) | (3,339,370) |
Warrants issued during the period | 0 | 4,046,836 |
Warrants exercised during the period | 0 | (365,224) |
Series E Warrants [Member] | ||
Balance | 2,046,082 | 0 |
Warrants reclassified to equity during the period | 1,996,435 | 6,128,344 |
Balance | 49,647 | 901,270 |
Net revaluation gain | (1,996,435) | (6,128,344) |
Warrants issued during the period | 0 | 7,029,614 |
May 2023 Warrants [Member] | ||
Balance | 0 | 0 |
Warrants reclassified to equity during the period | 1,910,710 | 0 |
Balance | 114,537 | 0 |
Net revaluation gain | (1,910,710) | 0 |
Warrants issued during the period | 2,025,247 | 0 |
The 2021 Warrants [Member] | ||
Balance | 0 | 306,704 |
Warrants reclassified to equity during the period | 0 | (18,652) |
Change in fair value to date of transfer to equity | 0 | (276,527) |
Movements in exchange rates | 0 | (11,525) |
Balance | 0 | 0 |
Net revaluation gain | 0 | 18,652 |
Series B Warrants [Member] | ||
Balance | 3,641 | 1,683,241 |
Warrants reclassified to equity during the period | (3,324) | 1,622,926 |
Movements in exchange rates | 0 | (59,975) |
Balance | 6,965 | 340 |
Net revaluation gain | 3,324 | (1,622,926) |
Series D Warrants [Member] | ||
Balance | 153,598 | 0 |
Warrants reclassified to equity during the period | 144,113 | 1,337,675 |
Movements in exchange rates | 0 | (51,319) |
Balance | 9,485 | 287,351 |
Net revaluation gain | (144,113) | (1,337,675) |
Warrants issued during the period | 0 | 3,080,121 |
Warrants exercised during the period | 0 | (1,403,776) |
January 2023 Warrants [Member] | ||
Balance | 352,437 | 0 |
Warrants reclassified to equity during the period | 347,443 | 0 |
Balance | 4,994 | 0 |
Net revaluation gain | (347,443) | 0 |
Warrants issued during the period | 0 | 0 |
September 2023 Warrants [Member] | ||
Balance | 0 | 0 |
Warrants reclassified to equity during the period | 1,270,101 | 0 |
Balance | 702,000 | 0 |
Net revaluation gain | (1,270,101) | 0 |
Warrants issued during the period | $ 1,972,101 | $ 0 |
Note 10 - Liability Related t_7
Note 10 - Liability Related to Warrants - Assumptions (Details) - Warrant [Member] | Dec. 31, 2023 | Sep. 26, 2023 | Mar. 15, 2023 | Jan. 12, 2023 | Dec. 31, 2022 |
Measurement Input, Share Price [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 12.8 | |||
Measurement Input, Share Price [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 12.8 | |||
Measurement Input, Share Price [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 12.8 | |||
Measurement Input, Share Price [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 8.8 | |||
Measurement Input, Share Price [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 12.8 | |||
Measurement Input, Share Price [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 12.8 | |||
Measurement Input, Share Price [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 21.2 | |||
Measurement Input, Share Price [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.53 | 1.35 | |||
Measurement Input, Exercise Price [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 448 | |||
Measurement Input, Exercise Price [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 92.8 | |||
Measurement Input, Exercise Price [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 64.8 | |||
Measurement Input, Exercise Price [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 13.2 | |||
Measurement Input, Exercise Price [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 448 | |||
Measurement Input, Exercise Price [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 92.8 | |||
Measurement Input, Exercise Price [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 21.2 | |||
Measurement Input, Exercise Price [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 2.5 | 2.5 | |||
Measurement Input, Expected Dividend Rate [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Expected Dividend Rate [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0 | 0 | |||
Measurement Input, Risk Free Interest Rate [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0386 | 0.0402 | |||
Measurement Input, Risk Free Interest Rate [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0386 | 0.0405 | |||
Measurement Input, Risk Free Interest Rate [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0389 | 0.0402 | |||
Measurement Input, Risk Free Interest Rate [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0387 | 0.0346 | |||
Measurement Input, Risk Free Interest Rate [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0386 | 0.0475 | |||
Measurement Input, Risk Free Interest Rate [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0386 | 0.0458 | |||
Measurement Input, Risk Free Interest Rate [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0399 | 0.0353 | |||
Measurement Input, Risk Free Interest Rate [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 0.0386 | 0.0462 | |||
Measurement Input, Expected Term [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.75 | 4.71 | |||
Measurement Input, Expected Term [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 5.16 | 4.48 | |||
Measurement Input, Expected Term [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.18 | 4.78 | |||
Measurement Input, Expected Term [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.71 | 5 | |||
Measurement Input, Expected Term [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.75 | 0.71 | |||
Measurement Input, Expected Term [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.75 | 1.48 | |||
Measurement Input, Expected Term [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.04 | 5 | |||
Measurement Input, Expected Term [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 4.5 | 5 | |||
Measurement Input, Price Volatility [Member] | Series A Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.338 | 0.942 | |||
Measurement Input, Price Volatility [Member] | Series C Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.298 | 0.941 | |||
Measurement Input, Price Volatility [Member] | Series E Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.371 | 0.936 | |||
Measurement Input, Price Volatility [Member] | May 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.341 | 1.109 | |||
Measurement Input, Price Volatility [Member] | Series B Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.338 | 1.357 | |||
Measurement Input, Price Volatility [Member] | Series D Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.338 | 1.124 | |||
Measurement Input, Price Volatility [Member] | January 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.416 | 0.982 | |||
Measurement Input, Price Volatility [Member] | September 2023 Warrants [Member] | |||||
Derivative warrant liabilities, assumption | 1.338 | 1.268 |
Note 11 - Capital and Other C_3
Note 11 - Capital and Other Components of Equity (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||||||||||
Oct. 10, 2023 | Sep. 26, 2023 | May 15, 2023 | May 15, 2023 | Mar. 15, 2023 | Mar. 10, 2023 | Feb. 15, 2023 | Oct. 06, 2022 | Oct. 01, 2022 | Sep. 09, 2022 | Jul. 13, 2022 | Jun. 24, 2022 | Jun. 23, 2022 | Aug. 31, 2022 | Dec. 31, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2021 | Nov. 03, 2023 | Apr. 27, 2023 | Jul. 12, 2022 | Feb. 19, 2021 | Mar. 31, 2020 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Payment, Tax Withholding, Share-Based Payment Arrangement | $ 0 | $ 574,153 | ||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 2,894,479 | 2,894,479 | 2,894,479 | |||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 6,648,437 | $ 6,648,437 | $ 6,648,437 | $ 6,155,323 | ||||||||||||||||||||||||
Restructuring Charges | 2,066,405 | $ 0 | 2,066,405 | 0 | ||||||||||||||||||||||||
Proceeds from Issuance of Long-Term Debt | 30,917,703 | 3,800,000 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | 645,921 | |||||||||||||||||||||||||||
Payments of Stock Issuance Costs | 1,521,640 | 1,330,211 | ||||||||||||||||||||||||||
Finance Costs | 1,602,981 | 1,362,776 | 6,570,787 | 2,658,305 | ||||||||||||||||||||||||
Unrealized Gain (Loss) on Derivatives | 1,596,901 | $ 8,367,871 | $ 7,186,846 | $ 16,083,681 | ||||||||||||||||||||||||
Stock Issued During Period, Value, Litigation Settlement | $ 2,750,000 | |||||||||||||||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Litigation Settlement (in shares) | 2,522,936 | |||||||||||||||||||||||||||
Settlement, Total | $ 4,250,000 | |||||||||||||||||||||||||||
Payments for Legal Settlements | 1,500,000 | |||||||||||||||||||||||||||
Stock Issued During Period, Value, Litigation Settlement | $ 2,750,000 | |||||||||||||||||||||||||||
Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 506,120 | 16,847 | 506,120 | 506,120 | 16,847 | 19,625 | 4,412 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 190.96 | $ 5,733.19 | $ 190.96 | $ 190.96 | $ 5,733.19 | $ 4,924.69 | $ 13,013.78 | |||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 0 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 1,348,652 | 16,139 | ||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in shares) | 0.0007 | 0.004 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, Litigation Settlement | $ 0 | |||||||||||||||||||||||||||
Secured Promissory Note Issued November 8, 2022 [Member] | ||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 550,000 | 550,000 | $ 550,000 | $ 550,000 | ||||||||||||||||||||||||
Secured Promissory Note Issued November 8, 2022 [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 3,659 | 3,659 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 96,578 | $ 96,578 | ||||||||||||||||||||||||||
Secured Promissory Note Issued August 26, 2022 [Member] | ||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 250,000 | 250,000 | 250,000 | $ 250,000 | ||||||||||||||||||||||||
Secured Promissory Note Issued August 26, 2022 [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 920 | 920 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 75,736 | $ 75,736 | ||||||||||||||||||||||||||
Secured Promissory Note [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | ||||||||||||||||||||||||||||
Proceeds from Issuance of Long-Term Debt | $ 3,000,000 | $ 3,000,000 | $ 3,000,000 | |||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 13,000,000 | $ 13,000,000 | $ 10,000,000 | |||||||||||||||||||||||||
Secured Promissory Note [Member] | Conversion of Borrowing Costs nto Common Stock [Member] | Morgan Stanley Expansion Capital ("MSEC") [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 9,317 | 9,317 | 9,317 | |||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 570,185 | $ 570,185 | $ 570,185 | |||||||||||||||||||||||||
September 2023 Direct Offering [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 250,000 | |||||||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 2.5 | |||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 4,500,000 | |||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | 506,278 | |||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 763,012 | |||||||||||||||||||||||||||
Payments of Stock Issuance Costs | 85,847 | |||||||||||||||||||||||||||
Finance Costs | 334,397 | |||||||||||||||||||||||||||
September 2023 Direct Offering [Member] | Warrants [Member] | ||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 342,768 | |||||||||||||||||||||||||||
May 2023 Direct Offering [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 110,380 | 110,380 | ||||||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 13.2 | $ 13.2 | $ 13.2 | |||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 4,000,000 | $ 4,000,000 | ||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | 719,513 | |||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 758,628 | |||||||||||||||||||||||||||
Payments of Stock Issuance Costs | 136,461 | |||||||||||||||||||||||||||
Finance Costs | 384,102 | |||||||||||||||||||||||||||
May 2023 Direct Offering [Member] | Warrants [Member] | ||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 238,065 | |||||||||||||||||||||||||||
September 2023 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,972,101 | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 250,000 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 2.5 | |||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 4,500,000 | |||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | 2,021,466 | |||||||||||||||||||||||||||
Proceeds from Issuance of Common Stock | 506,278 | |||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | 763,012 | |||||||||||||||||||||||||||
Payments of Stock Issuance Costs | 85,847 | |||||||||||||||||||||||||||
Finance Costs | 334,397 | |||||||||||||||||||||||||||
September 2023 Warrants [Member] | January 2023 Warrants [Member] | ||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $ 342,768 | |||||||||||||||||||||||||||
June 2022 Direct Offering [Member] | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 32,500 | |||||||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 102.8 | |||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 5,000,002 | |||||||||||||||||||||||||||
Payments of Stock Issuance Costs | 0 | |||||||||||||||||||||||||||
Finance Costs | $ 465,211 | |||||||||||||||||||||||||||
MSEC Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 92,495 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 66,404 | |||||||||||||||||||||||||||
Restructuring Charges | (2,066,405) | (2,066,405) | ||||||||||||||||||||||||||
September 2023 Pre-Funded Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.0001 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding | 394,000 | 394,000 | $ 394,000 | |||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,550,000 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 1,156,000 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 116 | |||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | $ 2,021,466 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 394,000 | |||||||||||||||||||||||||||
May 2023 Pre-Funded Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.004 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 0 | 0 | $ 0 | |||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 192,652 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 192,652 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 541 | $ 771 | ||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | 1,255,240 | |||||||||||||||||||||||||||
March 2023 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 21.6 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 37,723 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,778 | |||||||||||||||||||||||||||
Proceeds from Issuance of Long-Term Debt | $ 300,000 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
The 2020 Warrants and the 2021 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
June 2022 Pre-funded Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.04 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 16,140 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 65 | |||||||||||||||||||||||||||
Warrants IFF [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 16,800 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,429 | |||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | $ 0 | |||||||||||||||||||||||||||
Warrants AMI [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 11,200 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,983 | |||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | $ 0 | |||||||||||||||||||||||||||
Warrants AMI, Expiring October 3, 2024 [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,143 | |||||||||||||||||||||||||||
Warrants AMI, Expiring February 5, 2025 [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 840 | |||||||||||||||||||||||||||
The 2020 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | $ 3,150 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,524 | |||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | $ 19,058 | |||||||||||||||||||||||||||
The 2021 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | 2.5 | $ 3,150 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,911 | |||||||||||||||||||||||||||
Fair Value Adjustment of Warrants | $ 18,652 | |||||||||||||||||||||||||||
September 2023 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,800,000 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | $ 1,972,101 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | |||||||||||||||||||||||||||
May 2023 Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 13.2 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 303,032 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | 2,025,247 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 0 | |||||||||||||||||||||||||||
Pre-Funded Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.004 | |||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 16,140 | 0 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 65 | $ 541 | ||||||||||||||||||||||||||
Proceeds from Issuance of Warrants | $ 1,255,240 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 192,652 | |||||||||||||||||||||||||||
Series C Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 43,609 | 24,320 | 48,640 | |||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||||||||
Class of Warrant or Right, Extension Term (Year) | 2 years | |||||||||||||||||||||||||||
Derivative Liability | $ 4,046,836 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 5,031 | |||||||||||||||||||||||||||
Series D Warrants [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 24,320 | 48,640 | ||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 2 years | |||||||||||||||||||||||||||
Derivative Liability | $ 3,080,121 | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 24,320 | |||||||||||||||||||||||||||
June 2022 Common Warrant [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.5 | $ 13.2 | $ 13.2 | $ 92.8 | ||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 384,446 | |||||||||||||||||||||||||||
Proceeds from Warrant Exercises | $ 1,769,000 | |||||||||||||||||||||||||||
Unrealized Gain (Loss) on Derivatives | $ (2,126,955) | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in shares) | 92.8 | |||||||||||||||||||||||||||
Series C Warrants Expiring September 26, 2028 [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 19,289 | |||||||||||||||||||||||||||
Series D Warrants Expiring September 26, 2028 [Member] | ||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 24,320 | |||||||||||||||||||||||||||
Deferred Share Units ("DSUs") [Member] | Director [Member] | ||||||||||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | ||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 0 | $ 132.4 | ||||||||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member] | ||||||||||||||||||||||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in shares) | 0 | 0 | 6,563 | |||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 224 | |||||||||||||||||||||||||||
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) | 4,338 | |||||||||||||||||||||||||||
Payment, Tax Withholding, Share-Based Payment Arrangement | $ 815,953 | |||||||||||||||||||||||||||
Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member] | ||||||||||||||||||||||||||||
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings (in shares) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 5% | |||||||||||||||||||||||||||
Preferred Stock, Shares Issued (in shares) | 0 | 0 | 0 | |||||||||||||||||||||||||
Preferred Stock, Shares Outstanding (in shares) | 0 |
Note 11 - Capital and Other C_4
Note 11 - Capital and Other Components of Equity - Change in Value of Equity Related to Warrants (Details) - USD ($) | 9 Months Ended | ||||||
Sep. 26, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 03, 2023 | Mar. 31, 2023 | Mar. 10, 2023 | ||
Outstanding, number (in shares) | 2,894,479 | ||||||
Number of warrants outstanding (in shares) | 2,894,479 | ||||||
Warrants issued, value | $ 6,648,437 | $ 6,155,323 | |||||
The 2020 Warrants [Member] | |||||||
Warrants outstanding, weighted average exercise price (in dollars per share) | $ 2.5 | ||||||
The 2021 Warrants [Member] | |||||||
Warrants outstanding, weighted average exercise price (in dollars per share) | $ 2.5 | ||||||
March 2023 Warrants [Member] | |||||||
Warrants issued, value | $ 37,723 | ||||||
September 2023 Pre-Funded Warrants [Member] | |||||||
Warrants issued (in shares) | 1,550,000 | ||||||
Exercised (in shares) | (394,000) | ||||||
Warrants outstanding, weighted average exercise price (in dollars per share) | $ 0.0001 | ||||||
Warrants issued, value | $ 394,000 | ||||||
MSEC Warrants [Member] | |||||||
Number of warrants outstanding (in shares) | 92,495 | ||||||
Warrants issued, value | $ 66,404 | ||||||
Warrants Classified as Equity [Member] | |||||||
Outstanding, number (in shares) | 19,625 | ||||||
Outstanding, number (in shares) | 506,120 | ||||||
Number of warrants exercisable (in shares) | 506,120 | 19,625 | |||||
Number of warrants outstanding (in shares) | 506,120 | 19,625 | |||||
Warrants issued, value | $ 6,648,437 | $ 6,155,323 | |||||
Warrants Classified as Equity [Member] | Warrants IFF [Member] | |||||||
Outstanding, number (in shares) | [1] | 1,429 | |||||
Outstanding, number (in shares) | [1] | 1,429 | |||||
Number of warrants exercisable (in shares) | [1] | 1,429 | 1,429 | ||||
Number of warrants outstanding (in shares) | [1] | 1,429 | 1,429 | ||||
Warrants issued, value | [1] | $ 1,630,210 | $ 1,630,210 | ||||
Warrants Classified as Equity [Member] | Warrants AMI [Member] | |||||||
Outstanding, number (in shares) | [2] | 2,983 | |||||
Outstanding, number (in shares) | [2] | 2,983 | |||||
Number of warrants exercisable (in shares) | [2] | 2,983 | 2,983 | ||||
Number of warrants outstanding (in shares) | [2] | 2,983 | 2,983 | ||||
Warrants issued, value | [2] | $ 4,449,680 | $ 4,449,680 | ||||
Warrants Classified as Equity [Member] | The 2020 Warrants [Member] | |||||||
Outstanding, number (in shares) | [3] | 7,524 | |||||
Outstanding, number (in shares) | [3] | 7,524 | |||||
Number of warrants exercisable (in shares) | [3] | 7,524 | 7,524 | ||||
Number of warrants outstanding (in shares) | [3] | 7,524 | 7,524 | ||||
Warrants issued, value | [3] | $ 19,058 | $ 19,058 | ||||
Warrants Classified as Equity [Member] | The 2021 Warrants [Member] | |||||||
Outstanding, number (in shares) | [4] | 4,911 | |||||
Outstanding, number (in shares) | [4] | 4,911 | |||||
Number of warrants exercisable (in shares) | [4] | 4,911 | 4,911 | ||||
Number of warrants outstanding (in shares) | [4] | 4,911 | 4,911 | ||||
Warrants issued, value | [4] | $ 18,652 | $ 18,652 | ||||
Warrants Classified as Equity [Member] | March 2023 Warrants [Member] | |||||||
Outstanding, number (in shares) | 2,778 | ||||||
Outstanding, number (in shares) | 2,778 | ||||||
Number of warrants exercisable (in shares) | 2,778 | 2,778 | |||||
Number of warrants outstanding (in shares) | 2,778 | 2,778 | |||||
Warrants issued, value | $ 37,723 | $ 37,723 | |||||
Warrants Classified as Equity [Member] | September 2023 Pre-Funded Warrants [Member] | |||||||
Outstanding, number (in shares) | 0 | ||||||
Outstanding, number (in shares) | 394,000 | ||||||
Number of warrants exercisable (in shares) | 394,000 | 0 | |||||
Number of warrants outstanding (in shares) | 394,000 | 0 | |||||
Warrants issued, value | $ 426,710 | $ 0 | |||||
Warrants Classified as Equity [Member] | MSEC Warrants [Member] | |||||||
Outstanding, number (in shares) | 0 | ||||||
Outstanding, number (in shares) | 92,495 | ||||||
Number of warrants exercisable (in shares) | 92,495 | 0 | |||||
Number of warrants outstanding (in shares) | 92,495 | 0 | |||||
Warrants issued, value | $ 66,404 | $ 0 | |||||
Warrants [Member] | |||||||
Warrants outstanding, weighted average exercise price (in dollars per share) | $ 4,924.69 | $ 13,013.78 | |||||
Outstanding, number (in shares) | 19,625 | 4,412 | |||||
Issued, weighted average exercise price (in dollars per share) | $ 0.001 | $ 0.004 | |||||
Warrants issued (in shares) | 1,835,147 | 16,139 | |||||
Reclassification from liability related to warrants (in dollars per share) | $ 0 | $ 3,150 | |||||
Reclassification from liability related to warrants (in shares) | 0 | 12,435 | |||||
Exercised, weighted average exercise price (in shares) | 0.0007 | 0.004 | |||||
Exercised (in shares) | (1,348,652) | (16,139) | |||||
Warrants outstanding, weighted average exercise price (in dollars per share) | $ 190.96 | $ 5,733.19 | |||||
Outstanding, number (in shares) | 506,120 | 16,847 | |||||
Warrants exercisable, weighted average exercise price (in dollars per share) | $ 190.96 | $ 5,733.19 | |||||
Number of warrants exercisable (in shares) | 506,120 | 16,847 | |||||
Number of warrants outstanding (in shares) | 506,120 | 16,847 | 19,625 | ||||
[1]During the year ended March 31, 2020, Neptune granted 57,143 warrants (“Warrants IFF”) with an exercise price of $420.00 expiring on November 7, 2024. The warrants, granted in exchange for services to be rendered by non-employees, vested proportionally to the services rendered. The Warrants IFF fully vested in fiscal year ended March 31, 2022 and as such no expense was recognized in relation to those instruments since then.[2]During the year ended March 31, 2020, Neptune granted 119,286 warrants (“Warrants AMI”) with an exercise price of $280.00 with 85,715 expiring on October 3, 2024 and 33,572 expiring on February 5, 2025. The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. The Warrants AMI fully vested in fiscal year ended March 31, 2021 and as such no expense was recognized in relation to those instruments since then.[3]During the year ended March 31, 2021, Neptune issued a total of 300,926 warrants (“2020 Warrants”) with an exercise price of $78.75 expiring on October 22, 2025. The warrants, issued as part of the Private Placement entered into on October 20, 2020, are exercisable beginning anytime on or after April 22, 2021 until October 22, 2025. Initially classified as liability, the 2020 Warrants which had a fair value of $19,058 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares.[4]On February 19, 2021, the Corporation issued 196,429 warrants (“2021 Warrants”) with an exercise price of $78.75 expiring on August 19, 2026. The warrants, issued as part of a Registered Direct Offering entered into on February 17, 2021, are exercisable beginning anytime on or after August 19, 2021 until August 19, 2026. Initially classified as liability, the 2021 Warrants which had a fair value of $18,652 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. |
Note 12 - Non-controlling Int_3
Note 12 - Non-controlling Interest (Details Textual) | Dec. 31, 2023 | Nov. 03, 2023 | Sep. 30, 2023 | Aug. 17, 2023 | Mar. 31, 2023 | Feb. 10, 2021 |
Sprout Foods, Inc. [Member] | ||||||
Subsidiary, Ownership Percentage, Parent | 10.50% | 89.50% | 50.10% | 89.50% | 49.90% | 50.10% |
Note 12 - Non-Controlling int_4
Note 12 - Non-Controlling interest - Equity Interest Held by Non-controlling Interest (Details) | Dec. 31, 2023 | Nov. 03, 2023 | Sep. 30, 2023 | Aug. 17, 2023 | Mar. 31, 2023 | Feb. 10, 2021 |
Sprout Foods, Inc. [Member] | ||||||
Subsidiary, Ownership Percentage, Parent | 10.50% | 89.50% | 50.10% | 89.50% | 49.90% | 50.10% |
Note 12 - Non-controlling Int_5
Note 12 - Non-controlling Interest - Weighted Average Portion of Equity Interest Held by Non-controlling Interest (Details) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Sprout Foods, Inc. [Member] | ||||
Sprout | 23.80% | 49.90% | 41.20% | 49.90% |
Note 12 - Non-controlling Int_6
Note 12 - Non-controlling Interest - Summarized Financial Information (Details) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Mar. 31, 2022 | |
Revenue from contracts with customers | $ 7,611,836 | $ 11,945,092 | $ 26,913,567 | $ 39,668,246 | ||||
Selling, general and administrative expenses | (18,732,654) | (8,727,323) | (34,541,474) | (35,188,695) | ||||
Finance costs | (1,602,981) | (1,362,776) | (6,570,787) | (2,658,305) | ||||
Loss before tax | (19,170,482) | (495,438) | (34,307,482) | (44,275,095) | ||||
Income tax expense | 0 | 2,013 | 0 | 14,543 | ||||
Net loss | (17,749,338) | 1,288,110 | (26,953,896) | (33,893,698) | ||||
Total comprehensive loss | (19,211,931) | (728,941) | (34,694,272) | (51,014,769) | ||||
Loss attributable to the subsidiary's non-controlling interest | (1,421,144) | (1,785,561) | (7,353,586) | (10,395,940) | ||||
Comprehensive loss attributable to the subsidiary's non-controlling interest | (1,421,144) | (1,785,561) | (7,353,586) | (10,395,940) | ||||
Current assets | 16,599,734 | 16,599,734 | $ 23,550,173 | |||||
Current liabilities | 73,417,131 | 73,417,131 | 41,034,144 | |||||
Total equity (deficiency) | (52,221,565) | 15,923,853 | (52,221,565) | 15,923,853 | (27,560,669) | $ (38,259,532) | $ 15,596,395 | $ 60,837,599 |
Equity holders of the Company | (31,247,164) | (31,247,164) | (11,939,854) | |||||
Non-controlling interest | (20,974,401) | (20,974,401) | (15,620,815) | |||||
Cash flow provided by (used in) operating activities | (7,565,123) | (20,669,892) | (28,600,000) | |||||
Cash flow provided by investing activities | (79,208) | 2,690,035 | ||||||
Cash flow provided by (used in) financing activities | 6,975,561 | 12,895,705 | ||||||
Net increase (decrease) in cash and cash equivalents | (760,352) | (5,322,318) | ||||||
Sprout Foods, Inc. [Member] | ||||||||
Revenue from contracts with customers | 4,868,817 | 8,380,966 | 18,928,571 | 24,903,038 | ||||
Cost of sales | (4,347,787) | (7,825,211) | (18,896,730) | (23,748,469) | ||||
Selling, general and administrative expenses | (8,327,436) | (3,184,805) | (16,476,345) | (9,412,606) | ||||
Impairment loss on goodwill and intangible assets | 0 | 0 | 0 | (10,164,000) | ||||
Finance costs | (1,454,080) | (934,685) | (4,704,644) | (2,396,967) | ||||
Loss before tax | (9,260,486) | (3,563,735) | (21,149,148) | (20,819,004) | ||||
Income tax expense | 0 | (14,543) | 0 | (14,543) | ||||
Net loss | (9,260,486) | (3,578,278) | (21,149,148) | (20,833,547) | ||||
Total comprehensive loss | (9,260,486) | (3,578,278) | (21,149,148) | (20,833,547) | ||||
Loss attributable to the subsidiary's non-controlling interest | (1,421,144) | (1,803,089) | (7,353,586) | (2,220,145) | ||||
Comprehensive loss attributable to the subsidiary's non-controlling interest | (1,421,144) | (1,775,189) | (7,353,586) | (2,220,145) | ||||
Current assets | 7,712,019 | 7,712,019 | 12,382,450 | |||||
Non-current assets | 5,403 | 5,403 | 9,788 | |||||
Current liabilities | 43,561,652 | 43,561,652 | 12,938,219 | |||||
Non-current liabilities | 3,659,307 | 3,659,307 | 35,789,746 | |||||
Total equity (deficiency) | (39,503,537) | (39,503,537) | (36,335,727) | |||||
Equity holders of the Company | (46,872,028) | (46,872,028) | (20,714,912) | |||||
Non-controlling interest | 7,368,491 | 7,368,491 | $ (15,620,815) | |||||
Cash flow provided by (used in) operating activities | 85,994 | (1,873,210) | (2,491,563) | (5,798,310) | ||||
Cash flow provided by investing activities | 0 | 0 | 0 | 0 | ||||
Cash flow provided by (used in) financing activities | (409,260) | 1,999,408 | 2,496,437 | 5,249,408 | ||||
Net increase (decrease) in cash and cash equivalents | $ (323,266) | $ 126,198 | $ 4,874 | $ (548,902) |
Note 13 - Share-based Payment_2
Note 13 - Share-based Payment (Details Textual) | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | 15 Months Ended | 54 Months Ended | |||||||||
Jul. 08, 2019 $ / shares shares | Dec. 31, 2023 USD ($) shares | Dec. 31, 2022 USD ($) $ / shares shares | Sep. 30, 2023 | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2023 USD ($) shares | Dec. 31, 2023 USD ($) shares | Apr. 01, 2023 shares | Mar. 31, 2023 USD ($) shares | Apr. 01, 2022 shares | Mar. 31, 2022 shares | Nov. 14, 2021 USD ($) shares | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 0 | 5,744 | |||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 0 | $ 64.14 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | shares | 6,971 | 3,258 | 6,971 | 3,258 | 6,971 | 6,971 | |||||||||
Chief Executive Officer [Member] | Strategic Partnership [Member] | |||||||||||||||
Directors and Officers, Maximum Insurance Coverage | $ 15,000,000 | ||||||||||||||
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount | $ 6,900,000 | ||||||||||||||
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares) | shares | 212,500 | ||||||||||||||
Deferred Compensation Arrangement with Individual, Recorded Liability | $ 8,587 | $ 8,587 | $ 8,587 | $ 8,587 | |||||||||||
Deferred Compensation Arrangement with Individual, Distribution Paid | 0 | 8,587 | $ 3,263,437 | ||||||||||||
Deferred Compensation Arrangement with Individual, Compensation Expense | 110,859 | ||||||||||||||
Chief Executive Officer [Member] | Long-term Incentive [Member] | |||||||||||||||
Deferred Compensation Arrangement with Individual, Recorded Liability | 14,000 | 14,000 | 14,000 | 14,000 | $ 24,000 | ||||||||||
Deferred Compensation Arrangement with Individual, Compensation Expense | 10,000 | $ 65,688 | |||||||||||||
Deferred Compensation Arrangement with Individual, Maximum Payable | 15,000,000 | 15,000,000 | 15,000,000 | 15,000,000 | |||||||||||
Deferred Compensation Arrangement with Individual, Minimum US Market Capitalization | 1,000,000,000 | $ 1,000,000,000 | 1,000,000,000 | 1,000,000,000 | |||||||||||
General and Administrative Expense, Recovery | 5,000 | $ 1,000 | |||||||||||||
Share-Based Payment Arrangement, Employee [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | $ 63.6 | $ 0 | $ 63.6 | ||||||||||||
Share-Based Payment Arrangement, Nonemployee [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | 51,441 | $ 299,406 | $ 219,365 | $ 774,679 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 0 | ||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | 34,141 | 399,386 | $ 34,141 | $ 399,386 | $ 34,141 | $ 34,141 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 8 months 19 days | 1 year 10 days | |||||||||||||
Equity-based Awards [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | 433,494 | 1,005,455 | $ 1,516,920 | $ 2,832,438 | |||||||||||
Liability-based Awards [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | 0 | 110,859 | $ 0 | 3,263,437 | |||||||||||
Share-Based Payment Arrangement, Option [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum | 25% | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Per Holder | 20% | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum, Per Consultant | 2% | ||||||||||||||
Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month) | 18 months | ||||||||||||||
Non-market Performance Options [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | $ 0 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 2,500 | ||||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 6,202 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares) | shares | 0 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | shares | 0 | 0 | 0 | 0 | |||||||||||
Market Performance Options [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | $ 382,053 | 573,588 | $ 1,297,555 | 1,776,579 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 3,929 | ||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 7,769,175 | 9,484,197 | $ 7,769,175 | $ 9,484,197 | $ 7,769,175 | $ 7,769,175 | |||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 5 years 9 months 3 days | 6 years 9 months 3 days | |||||||||||||
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares | $ 6,202 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | shares | 536 | 536 | 536 | 536 | |||||||||||
Deferred Share Units ("DSUs") [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | $ 0 | $ 0 | $ 13,025 | ||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) | shares | 110 | 110 | 110 | 110 | 110 | 110 | 110 | 110 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | shares | 0 | 0 | |||||||||||||
Restricted Stock Units (RSUs) [Member] | |||||||||||||||
Share-Based Payment Arrangement, Expense | $ 0 | $ 154,284 | $ 0 | $ 2,037,960 | |||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month) | 3 years | ||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) | shares | 71 | 71 | 71 | 71 | 71 | 71 | 71 | 626 | |||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | shares | 0 | 6,743 | |||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Installments | 36 | ||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | $ 0 | $ 132.4 | |||||||||||||
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares | $ 224 | ||||||||||||||
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member] | Strategic Partnership [Member] | |||||||||||||||
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued | $ 132,681 | $ 0 | $ 1,555,585 | $ 235,683 | |||||||||||
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month) | 6 months | ||||||||||||||
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | |||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Month) | 3 years |
Note 13 - Share-based Payment -
Note 13 - Share-based Payment - Option Activity (Details) - $ / shares | 9 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
Options outstanding, weighted average exercise price (in dollars per share) | $ 729.32 | $ 1,496.49 |
Options outstanding, number of options (in shares) | 10,443 | 7,385 |
Granted (in dollars per share) | $ 0 | $ 64.14 |
Granted (in shares) | 0 | 5,744 |
Forfeited/Cancelled, weighted average exercise price (in dollars per share) | $ 100.03 | $ 640 |
Forfeited/Cancelled, number of options (in shares) | (2,978) | (1,650) |
Expired, weighted average exercise price (in dollars per share) | $ 0 | $ 2,028.4 |
Expired, number of options (in shares) | 0 | (956) |
Options outstanding, weighted average exercise price (in dollars per share) | $ 975.98 | $ 742 |
Options outstanding, number of options (in shares) | 7,465 | 10,523 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 995.86 | $ 1,570 |
Options exercisable, number of options (in shares) | 6,971 | 3,258 |
Note 13 - Share-based Payment_3
Note 13 - Share-based Payment - Exercise Price Range of Options (Details) | 9 Months Ended |
Dec. 31, 2023 $ / shares shares | |
Options outstanding, weighted remaining contractual life (Year) | 3 years 9 months 14 days |
Options outstanding, number of options (in shares) | shares | 7,465 |
Exercisable options, weighted number of options (in shares) | shares | 6,971 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 995.86 |
Range One [Member] | |
Exercise price, lower range (in dollars per share) | 62 |
Exercise price, upper range (in dollars per share) | $ 64 |
Options outstanding, weighted remaining contractual life (Year) | 3 years 7 months 17 days |
Options outstanding, number of options (in shares) | shares | 36 |
Exercisable options, weighted number of options (in shares) | shares | 12 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 62 |
Range Two [Member] | |
Exercise price, lower range (in dollars per share) | 64.01 |
Exercise price, upper range (in dollars per share) | $ 242.8 |
Options outstanding, weighted remaining contractual life (Year) | 3 years 8 months 26 days |
Options outstanding, number of options (in shares) | shares | 2,850 |
Exercisable options, weighted number of options (in shares) | shares | 2,850 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 65.6 |
Range Three [Member] | |
Exercise price, lower range (in dollars per share) | 242.81 |
Exercise price, upper range (in dollars per share) | $ 896 |
Options outstanding, weighted remaining contractual life (Year) | 3 years 1 month 9 days |
Options outstanding, number of options (in shares) | shares | 465 |
Exercisable options, weighted number of options (in shares) | shares | 167 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 470.3 |
Range Four [Member] | |
Exercise price, lower range (in dollars per share) | 896.01 |
Exercise price, upper range (in dollars per share) | $ 1,129.2 |
Options outstanding, weighted remaining contractual life (Year) | 2 years 7 months 13 days |
Options outstanding, number of options (in shares) | shares | 2,143 |
Exercisable options, weighted number of options (in shares) | shares | 2,143 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 1,022 |
Range Five [Member] | |
Exercise price, lower range (in dollars per share) | 1,129.21 |
Exercise price, upper range (in dollars per share) | $ 6,437.13 |
Options outstanding, weighted remaining contractual life (Year) | 5 years 3 months 25 days |
Options outstanding, number of options (in shares) | shares | 1,971 |
Exercisable options, weighted number of options (in shares) | shares | 1,799 |
Exercisable options, weighted average exercise price (in dollars per share) | $ 2,493.45 |
Note 13 - Share-based Payment_4
Note 13 - Share-based Payment - Market Performance Options (Details) - $ / shares | Dec. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 975.98 | $ 729.32 | $ 742 | $ 1,496.49 |
Options outstanding, number of options (in shares) | 7,465 | 10,443 | 10,523 | 7,385 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 995.86 | $ 1,570 | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | 6,971 | 3,258 | ||
Options exercisable, number of options (in shares) | 6,971 | 3,258 | ||
Market Performance Options [Member] | ||||
Options outstanding, weighted average exercise price (in dollars per share) | $ 6,202 | $ 6,202 | ||
Options outstanding, number of options (in shares) | 3,929 | 3,929 | ||
Options exercisable, weighted average exercise price (in dollars per share) | $ 6,202 | |||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares) | 536 | |||
Options exercisable, number of options (in shares) | 536 |
Note 13 - Share-based Payment_5
Note 13 - Share-based Payment - DSU Activity (Details) - Deferred Share Units ("DSUs") [Member] - $ / shares | Dec. 31, 2023 | Apr. 01, 2023 | Dec. 31, 2022 | Apr. 01, 2022 |
DSUs outstanding, weighted average share price (in dollars per share) | $ 2,657.95 | $ 2,657.95 | $ 2,657.95 | $ 2,657.95 |
DSUs outstanding, number (in shares) | 110 | 110 | 110 | 110 |
RSUs exercisable, weighted average share price (in dollars per share) | $ 2,657.95 | $ 2,657.95 | ||
RSUs exercisable, number (in shares) | 110 | 110 |
Note 13 - Share-based Payment_6
Note 13 - Share-based Payment - RSU Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 9 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2022 | |
RSUs outstanding, weighted average share price (in dollars per share) | $ 2,401.6 | $ 2,389.92 |
RSUs outstanding, number (in shares) | 71 | 626 |
Granted, weighted average share price (in dollars per share) | $ 0 | $ 132.4 |
Granted, number (in shares) | 0 | 10,917 |
Forfeited, weighted average share price (in dollars per share) | $ 0 | $ 770 |
Forfeited, number (in shares) | 0 | (391) |
Released through the issuance of common shares, weighted average share price (in dollars per share) | $ 0 | $ 224 |
Released through the issuance of common shares, number (in shares) | 0 | (6,743) |
Withheld as payment of withholding taxes, weighted average share price (in dollars per share) | $ 0 | $ 224 |
Withheld as payment of withholding taxes, number (in shares) | 0 | (4,338) |
RSUs outstanding, weighted average share price (in dollars per share) | $ 2,401.6 | $ 2,401.6 |
RSUs outstanding, number (in shares) | 71 | 71 |
RSUs exercisable, weighted average share price (in dollars per share) | $ 2,401.6 | $ 2,401.6 |
RSUs exercisable, number (in shares) | 71 | 71 |
Note 14 - Loss Per Share - Brea
Note 14 - Loss Per Share - Breakdown of Participating and Nonparticipating Warrants (Details) - shares | Dec. 31, 2023 | Nov. 03, 2023 | Mar. 31, 2023 | |
Number of warrants outstanding (in shares) | 2,894,479 | |||
Number of warrants participating (in shares) | 2,794,794 | |||
Number of warrants non-participating (in shares) | 99,685 | |||
Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | 506,120 | 19,625 | ||
Number of warrants participating (in shares) | 406,435 | |||
Number of warrants non-participating (in shares) | 99,685 | |||
Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 2,388,359 | |||
Number of warrants participating (in shares) | 2,388,359 | |||
Number of warrants non-participating (in shares) | 0 | |||
Series A Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 17,858 | |||
Number of warrants participating (in shares) | 17,858 | |||
Number of warrants non-participating (in shares) | 0 | |||
Series B Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 17,858 | |||
Number of warrants participating (in shares) | 17,858 | |||
Number of warrants non-participating (in shares) | 0 | |||
Series C Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 43,609 | |||
Number of warrants participating (in shares) | 43,609 | |||
Number of warrants non-participating (in shares) | 0 | |||
Series D Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 24,320 | |||
Number of warrants participating (in shares) | 24,320 | |||
Number of warrants non-participating (in shares) | 0 | |||
Series E Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 160,429 | |||
Number of warrants participating (in shares) | 160,429 | |||
Number of warrants non-participating (in shares) | 0 | |||
January 2023 Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 21,251 | |||
Number of warrants participating (in shares) | 21,251 | |||
Number of warrants non-participating (in shares) | 0 | |||
May 2023 Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 303,034 | |||
Number of warrants participating (in shares) | 303,034 | |||
Number of warrants non-participating (in shares) | 0 | |||
September 2023 Warrants [Member] | Warrant Classified as Liability [Member] | ||||
Number of warrants outstanding (in shares) | 1,800,000 | |||
Number of warrants participating (in shares) | 1,800,000 | |||
Number of warrants non-participating (in shares) | 0 | |||
Warrants IFF [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | [1] | 1,429 | 1,429 | |
Number of warrants participating (in shares) | 0 | |||
Number of warrants non-participating (in shares) | 1,429 | |||
Warrants AMI [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | [2] | 2,983 | 2,983 | |
Number of warrants participating (in shares) | 0 | |||
Number of warrants non-participating (in shares) | 2,983 | |||
The 2020 Warrants [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | [3] | 7,524 | 7,524 | |
Number of warrants participating (in shares) | 7,524 | |||
Number of warrants non-participating (in shares) | 0 | |||
The 2021 Warrants [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | [4] | 4,911 | 4,911 | |
Number of warrants participating (in shares) | 4,911 | |||
Number of warrants non-participating (in shares) | 0 | |||
March 2023 Warrants [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | 2,778 | 2,778 | ||
Number of warrants participating (in shares) | 0 | |||
Number of warrants non-participating (in shares) | 2,778 | |||
September 2023 Pre-Funded Warrants [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | 394,000 | 0 | ||
Number of warrants participating (in shares) | 394,000 | |||
Number of warrants non-participating (in shares) | 0 | |||
MSEC Warrants [Member] | ||||
Number of warrants outstanding (in shares) | 92,495 | |||
MSEC Warrants [Member] | Warrants Classified as Equity [Member] | ||||
Number of warrants outstanding (in shares) | 92,495 | 0 | ||
Number of warrants participating (in shares) | 0 | |||
Number of warrants non-participating (in shares) | 92,495 | |||
[1]During the year ended March 31, 2020, Neptune granted 57,143 warrants (“Warrants IFF”) with an exercise price of $420.00 expiring on November 7, 2024. The warrants, granted in exchange for services to be rendered by non-employees, vested proportionally to the services rendered. The Warrants IFF fully vested in fiscal year ended March 31, 2022 and as such no expense was recognized in relation to those instruments since then.[2]During the year ended March 31, 2020, Neptune granted 119,286 warrants (“Warrants AMI”) with an exercise price of $280.00 with 85,715 expiring on October 3, 2024 and 33,572 expiring on February 5, 2025. The warrants, granted in exchange for services to be rendered by non-employees, vest proportionally to the services rendered. The Warrants AMI fully vested in fiscal year ended March 31, 2021 and as such no expense was recognized in relation to those instruments since then.[3]During the year ended March 31, 2021, Neptune issued a total of 300,926 warrants (“2020 Warrants”) with an exercise price of $78.75 expiring on October 22, 2025. The warrants, issued as part of the Private Placement entered into on October 20, 2020, are exercisable beginning anytime on or after April 22, 2021 until October 22, 2025. Initially classified as liability, the 2020 Warrants which had a fair value of $19,058 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares.[4]On February 19, 2021, the Corporation issued 196,429 warrants (“2021 Warrants”) with an exercise price of $78.75 expiring on August 19, 2026. The warrants, issued as part of a Registered Direct Offering entered into on February 17, 2021, are exercisable beginning anytime on or after August 19, 2021 until August 19, 2026. Initially classified as liability, the 2021 Warrants which had a fair value of $18,652 were reclassified as equity on October 1, 2022 as a result of the change in functional currency. The holders of these warrants will be entitled to participate in dividends and other distributions of assets by the Company to its holders of common shares as though the holder then held common shares. |
Note 14 - Loss Per Share - Basi
Note 14 - Loss Per Share - Basic and Dilutive Loss Per Share (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Net loss | $ (17,749,338) | $ 1,288,110 | $ (26,953,896) | $ (33,893,698) |
Less: Undistributed earnings attributed to warrant holders | 0 | (620,910) | 0 | 0 |
Basic and dilutive income (loss) attributed to common shareholders | $ (17,749,338) | $ 667,200 | $ (26,953,896) | $ (33,893,698) |
Basic weighted-average number of common shares outstanding (in shares) | 4,285,229 | 284,619 | 1,784,047 | 237,013 |
Options, RSU's, DSU's (in shares) | 0 | 71 | 0 | 0 |
Dilutive weighted-average number of common shares outstanding (in shares) | 4,285,229 | 284,690 | 1,784,047 | 237,013 |
Basic and dilutive loss per share (in dollars per share) | $ (4.14) | $ 2.34 | $ (15.11) | $ (143) |
Note 14 - Loss Per Share - Anti
Note 14 - Loss Per Share - Antidilutive Securities (Details) - shares | 3 Months Ended | 9 Months Ended | 15 Months Ended | |
Dec. 31, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | |
Share-Based Payment Arrangement [Member] | ||||
Antidilutive securities (in shares) | 14,075 | 14,075 | 17,133 | 17,062 |
Warrant [Member] | ||||
Antidilutive securities (in shares) | 2,407,984 | 2,407,984 | 280,917 | 280,917 |
Note 15 - Fair-value Measurem_3
Note 15 - Fair-value Measurements (Details Textual) | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||
Mar. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Mar. 31, 2023 USD ($) | Jan. 01, 2023 | Feb. 10, 2022 | |
Unrealized Gain (Loss) on Derivatives | $ 1,596,901 | $ 8,367,871 | $ 7,186,846 | $ 16,083,681 | ||||
Sprout Foods, Inc. [Member] | ||||||||
Derivative Asset, Measurement Input | 0 | |||||||
Unrealized Gain (Loss) on Derivatives | $ (5,598,198) | $ 0 | $ (5,598,198) | |||||
Sprout Foods, Inc. [Member] | Measurement Input, Revenue Multiple [Member] | ||||||||
Derivative Asset, Measurement Input | 2.3 | 3 | ||||||
Sprout Foods, Inc. [Member] | Measurement Input, EBITDA Multiple [Member] | ||||||||
Derivative Asset, Measurement Input | 12 | 15 | ||||||
Sprout Foods, Inc. [Member] | Measurement Input, Discount for Lack of Marketability [Member] | ||||||||
Derivative Asset, Measurement Input | 0.20 | 0.50 | ||||||
Sprout Foods, Inc. [Member] | ||||||||
Subsidiary, Ownership Percentage, Noncontrolling Owner | 49.90% |
Note 15 - Fair-value Measurem_4
Note 15 - Fair-value Measurements - Financial Assets and Liabilities (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Liability related to warrants | $ 6,648,437 | $ 6,155,323 |
Fair Value, Recurring [Member] | ||
Liability related to warrants | 911,790 | 3,156,254 |
Other liability | 14,000 | 24,000 |
Total | 925,790 | 3,180,254 |
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Liability related to warrants | 0 | 0 |
Other liability | 0 | 0 |
Total | 0 | 0 |
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Liability related to warrants | 0 | 0 |
Other liability | 0 | 0 |
Total | 0 | 0 |
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Liability related to warrants | 911,790 | 3,156,254 |
Other liability | 14,000 | 24,000 |
Total | $ 925,790 | $ 3,180,254 |
Note 16 - Commitments and Con_2
Note 16 - Commitments and Contingencies (Details Textual) | 9 Months Ended | 12 Months Ended | ||||||||||||||||
Oct. 10, 2023 shares | Aug. 23, 2023 USD ($) | Mar. 22, 2023 USD ($) | Feb. 28, 2023 USD ($) | Oct. 21, 2022 USD ($) | Oct. 11, 2022 USD ($) | Jul. 07, 2022 USD ($) | May 28, 2021 USD ($) | Aug. 10, 2020 USD ($) | Jan. 31, 2020 USD ($) | Dec. 31, 2023 USD ($) | Mar. 31, 2023 USD ($) | Nov. 03, 2023 $ / shares | Sep. 30, 2023 USD ($) | Feb. 10, 2022 | Feb. 11, 2021 | Mar. 31, 2019 | Mar. 21, 2019 | |
Sprout Foods, Inc. [Member] | ||||||||||||||||||
Business Acquisition, Percentage of Voting Interests Acquired | 50.10% | 50.10% | ||||||||||||||||
Claims Made Regarding Certain Royalty Payments by Former CEO[Member] | ||||||||||||||||||
Percentage of Royalties Payable | 1% | 1% | ||||||||||||||||
Loss Contingency Accrual | $ 1,137,882 | $ 963,808 | ||||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | ||||||||||||||||||
Loss Contingency Accrual | 0 | |||||||||||||||||
Loss Contingency, Damages Paid, Value | $ 500,000 | |||||||||||||||||
Loss Contingency, Damages Paid, Value, Per Installment | $ 500,000 | |||||||||||||||||
Litigation Settlement, Expense Payable in Shares | $ 2,750,000 | |||||||||||||||||
Stock Issued During Period, Shares, Litigation Settlement (in shares) | shares | 2,522,936 | |||||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | Minimum [Member] | ||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,000,000 | |||||||||||||||||
Marvin Gong v. Neptune Wellness Solutions, et al. [Member] | Maximum [Member] | ||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,250,000 | |||||||||||||||||
Claim and Demand For Arbitration Against Peter M. Galloway and PMGSL Holdings, LLC [Member] | ||||||||||||||||||
Loss Contingency Accrual | 4,157,014 | 600,000 | ||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 4,000,000 | $ 68,000 | ||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party, Before Fees | $ 2,200,000 | |||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party, Interest Rate | 10.50% | |||||||||||||||||
Claim and Demand for Arbitration by Iron Lab, S.A. de C.V. [Member] | ||||||||||||||||||
Loss Contingency Accrual | 0 | |||||||||||||||||
Claims Alleging Products Contain Unsafe Levels of Heavy Metals [Member] | ||||||||||||||||||
Loss Contingency Accrual | 0 | |||||||||||||||||
Lawsuit Alleging Personal Injury From the Ingestion of Products [Member] | ||||||||||||||||||
Loss Contingency Accrual | $ 0 | |||||||||||||||||
Loss Contingency, Number of Lawsuits | 4 | |||||||||||||||||
Carolina Rework Solutions, LLC v, Neptune Health & Wellness Innovation, Inc. [Member] | ||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 2,000,000 | $ 2,000,000 | 315,909 | |||||||||||||||
Carolina Rework Solutions, LLC v, Neptune Health & Wellness Innovation, Inc. [Member] | Alleged Breach of Warehousing Contract [Member] | ||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 175,534 | |||||||||||||||||
Carolina Rework Solutions, LLC v, Neptune Health & Wellness Innovation, Inc. [Member] | Minimum [Member] | Additional Unspecified Damages [Member] | ||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 1,000,000 | |||||||||||||||||
Freight Connections v. Neptune Health & Wellness Innovation, Inc. [Member] | ||||||||||||||||||
Loss Contingency, Damages Sought, Value | $ 328,168 | |||||||||||||||||
Exclusive License Agreement For Specialty Ingredient [Member] | ||||||||||||||||||
License Agreement, Period (Year) | 8 years | |||||||||||||||||
License Agreement, Remaining Amount of Minimum Royalties | $ 148,502 | |||||||||||||||||
License Agreement Relating to Children's Entertainment Property [Member] | Moonbug Entertainment Limited [Member] | ||||||||||||||||||
Loss Contingency Accrual | $ 74,167 | $ 98,786 | ||||||||||||||||
License Agreement, Minimum Annual Payment | $ 200,000 | |||||||||||||||||
License Agreement, Extension Period (Year) | 3 years | |||||||||||||||||
Restructuring Agreement, All Shares of Sprout Common Stock, Held by MSEC [Member] | ||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 0.2 |
Note 17 - Operating Segments (D
Note 17 - Operating Segments (Details Textual) | 9 Months Ended |
Dec. 31, 2023 | |
Number of Operating Segments | 1 |
Note 17 - Operating Segments -
Note 17 - Operating Segments - Revenue By Geographical Locations (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues | $ 7,599,752 | $ 12,208,908 | $ 26,967,457 | $ 40,467,978 |
CANADA | ||||
Revenues | 875,338 | 1,347,700 | 3,101,950 | 7,074,759 |
UNITED STATES | ||||
Revenues | 6,700,451 | 10,597,392 | 23,794,546 | 32,626,483 |
Other Countries [Member] | ||||
Revenues | $ 23,963 | $ 263,816 | $ 70,961 | $ 766,736 |
Note 17 - Operating Segments _2
Note 17 - Operating Segments - Long-lived Assets By Geographical Locations (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Property, plant and equipment | $ 1,035,423 | $ 1,403,264 |
Intangible assets | 1,308,849 | 1,607,089 |
Goodwill | 2,482,706 | 2,426,385 |
CANADA | ||
Property, plant and equipment | 196,408 | 250,921 |
Intangible assets | 1,308,849 | 1,607,089 |
Goodwill | 2,482,706 | 2,426,385 |
UNITED STATES | ||
Property, plant and equipment | $ 839,015 | $ 1,152,343 |
Note 17 - Operating Segments _3
Note 17 - Operating Segments - Revenues (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue from sales | $ 7,611,836 | $ 11,945,092 | $ 26,913,567 | $ 39,668,246 |
Transferred at Point in Time [Member] | ||||
Revenue from sales | 7,611,836 | 11,945,092 | 26,913,567 | 39,668,246 |
Transferred at Point in Time [Member] | Nutraceutical Products [Member] | ||||
Revenue from sales | 2,743,019 | 3,541,002 | 7,984,996 | 11,844,529 |
Transferred at Point in Time [Member] | Cannabis and Hemp Products [Member] | ||||
Revenue from sales | 0 | 23,337 | 0 | 2,740,664 |
Transferred at Point in Time [Member] | Food and Beverages Products [Member] | ||||
Revenue from sales | $ 4,868,817 | $ 8,380,753 | $ 18,928,571 | $ 25,083,053 |